,Name,Binds_to,Origin,VH,VL,Reference,Description,Date_added
0,K398.22,SARS-CoV,Macaca mulatta (Rhesus monkey),evqlaesggglvkpggslrlscvasgftfssnemhwvrqapgkglewvsvisesgftteyadsvkgrftisrdnaknslflqmnslraedtavyyctrvsifgqfivatyfdywgqgvlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qaaltqprsvsgspgqsvtisctgtssdiggynyvswyqqhpgtapklmiyavserpsgvsdrfsgsksgntasltisglqaedeadyyccsyagtvlfgggtrltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"He,W. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Unpublished; 2022.","VH: Chain H, K398.22 heavy chain / VL: Chain L, K398.22 light chain",2022-03-01
1,K288.2,SARS-CoV,Macaca mulatta (Rhesus monkey),evrlvesggglvkpggslrlscvasgftfssyemhwvrqapgkglewvsvisesgatthytdsvkgrftisrdnaknslflqmnslraedtavyyctrpqsvtvfgvaatsyeafdfwgqglrvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,divmtqspdtlslspgetatlscrasqsvssyvawyqqkpeqpprlliygsssratgmpdrfsgsgsgtdftltisslepddfavyycqqytnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"He,W. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Unpublished; 2022.","VH: Chain H, K288.2 heavy chain / VL: Chain L, K288.2 light chain",2022-03-01
2,FI3A,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvs,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdik,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.","VH: Chain Y, FI3A fab heavy chain / VL: Chain Z, FI3A fab Light chain",2022-03-01
3,FD-5D,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycaspggitaagtsvlfgyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpitwtfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.","VH: Chain G, FD-5D Fab heavy chain / VL: Chain F, FD-5D Fab light chain",2022-03-01
6,FD-11A,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgpdiltgyynyyyygmdvwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgfyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.","VH: Chain A, FD-11A Fab heavy chain / VL: Chain B, FD-11A Fab light chain",2022-03-01
7,FI-3A,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Huang,K.A. et al.; Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2; Theranostics 12 (1), 1-17 (2022); 2022.","VH: Chain H, FI-3A Fab heavy chain / VL: Chain L, FI-3A Fab light chain",2022-03-01
10,DH1058,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgfnfgdfgmhwvrqapgkglewvavisyegrnknhadsvrgrftisrdnsrnmlylqmnslrrgdtavyycakenrdrnydswsasysdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspsflsasvgdrvtitcrasqgidrylawyqqkpgsapklliyaastlqsgvpsrfsgsgsetdftltisslqpddfatyycqqlstyptitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Gobeil,S.M. et al.; Structural diversity of the SARS-CoV-2 Omicron spike; bioRxiv (2022); 2022.","VH: Chain A, DH1058 Fab heavy chain / VL: Chain B, DH1058 Fab Light chain",2022-03-01
12,DH1042,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaylelsslrsedtavyycarymvtrdqyyydmdvwgqgttvtvs,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysppptfgqgtklei,"Gobeil,S.M. et al.; Structural diversity of the SARS-CoV-2 Omicron spike; bioRxiv (2022); 2022.","VH: Chain d, DH1042 heavy chain / VL: Chain b, DH1042 light chain",2022-03-01
15,S304,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.","VH: Chain M, S304 Fab heavy chain / VL: Chain N, S304 Fab light chain",2022-03-01
17,S309,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.","VH: Chain C, S309 heavy chain / VL: Chain D, S309 light chain",2022-03-01
19,S309,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,ivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkve,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.","VH: Chain N, S309 Fab Heavy Chain / VL: Chain O, S309 Fab light chain",2022-03-01
22,S2L20,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfnsygmhwvrqapgkglewvafirydggnkyyadsvkgrftisrdnskntlylqmkslraedtavyycanlkdsrysgsyydywgqgtlvtvss,viwmtqspsslsasvgdrvtitcqasqdirfylnwyqqkpgkapkllisdasnmetgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpftfgpgtkvdfk,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.","VH: Chain I, S2L20 Fab heavy chain / VL: Chain H, S2L20 Fab light chain",2022-03-01
26,S309,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvs,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"McCallum,M. et al.; Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement; Science, eabn8652 (2022) In press; 2022.","VH: Chain A, S309 Fab heavy chain / VL: Chain B, S309 Fab light chain",2022-03-01
27,S2K146,not determined,Homo sapiens (human),qvqlvesggvvvqpggslrlscaasgftfhdhtmhwvrqapgkglewvslitwnggtihysdsvkgrftisrdnsknslylqmnslrtedtalyycakdlgrggwylpsdawgqgtlvtvss,qsvltqppsasgtpgqrvtiscsgssanigsntvnwyqhlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslkgvfgggtkltvl,"Park,Y.J. et al.; Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry; Science 375 (6579), 449-454 (2022); 2022.","VH: Chain F, S2K146 Fab heavy chain / VL: Chain G, S2K146 Fab light chain",2022-03-01
31,CV38-142,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkiscqgsgysftsywigwvrqmpgkglewmgiiypgesdtrysssfqghvtisadksistaylqwsslkasdtamyycarirgvyssgwiggdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprqwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Liu,H. et al.; A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection; bioRxiv (2021); 2021.","VH: Chain H, CV38-142 Fab heavy chain / VL: Chain L, CV38-142 Fab light chain",2022-03-01
33,COVA1-16,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Liu,H. et al.; A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection; bioRxiv (2021); 2021.","VH: Chain H, COVA1-16 Fab heavy chain / VL: Chain L, COVA1-16 Fab light chain",2022-03-01
34,COVA1-16,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,H. et al.; Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity; bioRxiv (2020); 2020.","VH: Chain H, COVA1-16 heavy chain / VL: Chain L, COVA1-16 light chain",2022-03-01
36,AB-3467,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyhwnwirqppgkglewigyiyysgntnynpslksrvsistdtsknqfslklssvtaadtavyycvremrrgysgydywdlyafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyphtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Burnett,D.L. et al.; Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability; Immunity 54 (12), 2908-2921 (2021); 2022.","VH: Chain H, AB-3467 Fab Heavy Chain / VL: Chain L, AB-3467 Fab Light Chain",2022-03-01
38,BETA-43,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnnfyadsvkgrftisrdnfkntlylqmnslraedtavyycarsycsggfcfgyyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvapgktatitcggnnigtksvhwyqqkpgqapvlviyynsdrpsgiperfsgsnsgntvtltisrveagdeadyycqvwdsgsdhyvfgtgtkvtvvgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain A, Beta-43 heavy chain / VL: Chain B, Beta-43 Fab light chain",2022-03-01
40,BETA-50,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasrgtfntyvftwvrqapgqglewmggiipffgtadyaqkfqgrvtitaddststaymelsslrsedtavyycsrlsqwdllpmwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspgtlslspgeratlscrasqsftssylawyqqkpgqaprlliygassratgipdrfsgtgsgtdftltisrlepedfavyycqqygtsprmytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain A, Beta-50 Fab heavy chain / VL: Chain B, Beta-50 Fab light chain",2022-03-01
41,BETA-54,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvfggsitssnhywvwirqppgkglewigsmyysgstaynpsltnrvtisvdtsknqfslklssvtaadtavyycarqigpkrpsqvadwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain H, Beta-54 Fab heavy chain / VL: Chain L, Beta-54 Fab light chain",2022-03-01
42,BETA-49,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfsssviswvrqapgqglewmggiiplfgsanyaqkfqgrvtitadeststaymemtslrsedtavyycakvsqwalilfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspswtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain A, Beta-49 Fab heavy chain / VL: Chain B, Beta-49 Fab light chain",2022-03-01
43,FI-3A,SARS-CoV-2,Homo sapiens (human),evqllesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardhvrpgmniwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpvtfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain H, FI-3A Fab heavy chain / VL: Chain L, FI-3A Fab light chain",2022-03-01
44,BETA-06,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisssshywgwirqppgkglewigsiyysesayynpslksrvtmsidtsknqfslklnsvtaadtavyycarvteprwtscyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivmtqspatlslspgeratlscrtsqsvtsylawyqqrpgqaprlliydasdratgiparfsgsgsgtdftltisnlepedfavyycqlrsnwppitfgqgtrletkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain J, Beta-06 heavy chain / VL: Chain K, Beta-06 light chain",2022-03-01
47,BETA-53,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgeslrisckgsghnspsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslqasdtaiyycarhvvalthlypdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspatlsvspgeratlscrasqsvsstlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwstwtfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain E, Beta-53 fab heavy chain / VL: Chain F, Beta-53 fab light chain",2022-03-01
50,BETA-32,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittgymelsslrsddtalyycarvgahdyydssdnwfdpwgqgtlvtvfsastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspssvsasvgdrltitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain D, Beta-32 heavy chain / VL: Chain E, Beta-32 light chain",2022-03-01
52,BETA-26,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsgasisnyywswirqppgkglewvgyiyytgstnhnpslksrvtisldtsknqfslrlssvtaadtavyycaraycsggscfdtfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvapgqtaritcggnnigsksvhwfqqkpgqapvlvvyddsdrpsgiperfsgsnsgntasltisrveagdeadyycqvwdsasdsgvfgtgtkltvpgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain J, Beta-26 heavy chain / VL: Chain K, Beta-26 light chain",2022-03-01
58,COVOX-222,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycargegspgnwfdpwgqgtlvtvss,dvvmtqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqhydtsprfgggtkvdik,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain E, COVOX-222 heavy chain / VL: Chain F, COVOX-222 light chain",2022-03-01
63,BETA-40,SARS-CoV-2,Homo sapiens (human),qvqlvesgpgqvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgsayynpslksrvtisvdtsknqfslklnsvtaadtavfycarhaapspgdnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qsvltqppsvsvspgqtaritcsgdalstqngnwyqqkpgqapvmvickdserpsgiperfsgsrsgttvtltisgvqaedeadyhcqsadnrahvvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain H, Beta-40 heavy chain / VL: Chain B, Beta-40 Fab light chain",2022-03-01
65,BETA-44,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwispyngnthyaqklqgrvtmttdtststaymelrslrsddtavyycardgellgwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvvtqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyagskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecsec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain C, Beta-44 Fab heavy chain / VL: Chain D, Beta-44 Fab light chain",2022-03-01
67,BETA-47,SARS-CoV-2,Homo sapiens (human),qvqlvesgpemkkpgtsvkvsckasgftfitsavqwvrqargqrlewmgwiavgsgntnyaqkfqdrvtinrdmststaymelsslrsedtavyycaaphcnrtschdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqsvsrnylawyqqkpgqvprlliygassratgipdrfrgsgsgtdftltinrlesedfavyycqqygsslftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain H, Beta-47 Fab heavy chain / VL: Chain L, Beta-47 Fab light chain",2022-03-01
68,BETA-38,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnywigwvrqmpgkglewmgiiypgdsgtryspsfqgqvtisadksirtaylqwsslkasdsamyycarsrvgatggyydyymdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qsvltqppsasgtpgqrvtiscsgsssnlggntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain B, Beta-38 Fab heavy chain / VL: Chain C, Beta-38 Fab light chain",2022-03-01
71,BETA-29,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygmhrvrqapgkglewvalisyeesnryygdsvrgrftisrdnskntlylqmnslrpedtavyycakdqgpatvmvtairgamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyfgspsitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain A, Beta-29 Fab heavy chain / VL: Chain B, Beta-29 Fab light chain",2022-03-01
72,BETA-27,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgltvrsnymnwvrqapgkglewvsliysggstfyadsvkgrftisrhdskntlylqmnslraedtavyycardlvvygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgeratlscrasqsvsssslawyqqkhgqaprlliygtssratgipdrfsgsgsgtdftltisglepedfavyycqqygssplfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain A, Beta-27 Fab heavy chain / VL: Chain B, Beta-27 Fab light chain",2022-03-01
73,BETA-24,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpglvkpsqtlsltcsvsdgsisssdyywswirqppgkglewigyiyytgstyynpslksrvsisvdrsknqfslklssvtaadtavyycarlvvpspkgswfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqpasvsgspgqsitisctgtsidvgnynlaswyqqhpgkapkliiyegsrrpsgvsnrfsgaksgntasltisglqaedeadyyccsyvgsstyvfgsgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain B, Beta-24 heavy chain / VL: Chain C, Beta-24 light chain",2022-03-01
75,BETA-22,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygihwvrqapgkglewvavisydgshkyyadsvkgrftisrdnskntlylqmnslktedtavyycakdssaaipyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,aiqmtqspdslavslgeratinckssqsilynsnnktylawyqqkpgqppkllifwastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiplifgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain H, Beta-22 Fab heavy chain / VL: Chain L, Beta-22 Fab light chain",2022-03-01
76,BETA-6,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisssshywgwirqppgkglewigsiyysesayynpslksrvtmsidtsknqfslklnsvtaadtavyycarvteprwtscyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivmtqspatlslspgeratlscrtsqsvtsylawyqqrpgqaprlliydasdratgiparfsgsgsgtdftltisnlepedfavyycqlrsnwppitfgqgtrletkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain C, Beta-6 Fab heavy chain / VL: Chain D, Beta-6 Fab light chain",2022-03-01
77,COVOX-45,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggsyayyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftitslqpediatyycqqydnlpltfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants; Cell Host Microbe 30 (1), 53-68 (2022); 2021.","VH: Chain F, COVOX-45 Fab heavy chain / VL: Chain G, COVOX-45 Fab light chain",2022-03-01
81,BETA-49,not determined,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfsssviswvrqapgqglewmggiiplfgsanyaqkfqgrvtitadeststaymemtslrsedtavyycakvsqwalilfwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspswtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Afonine,P.V. et al.; Real-space refinement in PHENIX for cryo-EM and crystallography; Acta Crystallogr., Sect. D: Biol. Crystallogr. 74, 531 (2018); 2021.","VH: Chain J, Beta-49 heavy chain / VL: Chain K, Beta-49 light chain",2022-03-01
84,CV3-25,SARS-CoV,Homo sapiens (human),evqlvesgaevkkpgeslkisckgsgytftrywigwvrqmpgkglewmgiiypgdsdtryspsfqghvtisadksistaylqwnslkasdtamyycarlpqycsngvcqrwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,eivltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpytfgqgtnleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Zhou,P. et al.; A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes; bioRxiv (2021); 2021.","VH: Chain A, CV3-25 Fab Heavy Chain / VL: Chain B, CV3-25 Fab Light Chain",2022-03-01
86,LY-COV1404,SARS-CoV-2,Homo sapiens (human),xitlkesgptlvkptqtltltctfsgfslsisgvgvgwlrqppgkalewlaliywdddkryspslksrltiskdtsknqvvlkmtnidpvdtatyycahhsistifdhwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,qsaltqpasvsgspgqsitisctatssdvgdynyvswyqqhpgkapklmifevsdrpsgisnrfsgsksgntasltisglqaedeadyycssyttssavfgggtkltvlgrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Westendorf,K. et al.; LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants; bioRxiv (2022); 2021.","VH: Chain D, LY-CoV1404 Fab heavy chain / VL: Chain E, LY-CoV1404 Fab light chain",2022-03-01
88,P36-5D2,SARS-CoV-2,Homo sapiens (human),mgwsciilflvatatgvhsqvqlvqsgaevkkpgasvkvsckasgytfttyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyycaggggrrlqfdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,mgwsciilflvatatgvhsdiqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyngypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Shan,S. et al.; A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants; Front Immunol 12, 766821 (2021); 2021.","VH: Chain g, P36-5D2 heavy chain / VL: Chain f, P36-5D2 light chain",2022-03-01
94,GAMMA-1,SARS-CoV-2,Homo sapiens (human),evqlvqsggglvkpggslrlscaasgitvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargeggsivgvtsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,asdiqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgseteftltisslhpddfatyycqqsystlpytfgqgtkveikrtaaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhklyacevthqglsspvtksfnrgec,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.","VH: Chain K, Immunoglobulin gamma-1 heavy chain / VL: Chain O, Immunoblobulin light chain",2022-03-01
98,WRAIR-2151,SARS-CoV-2,Homo sapiens (human),qvqlqesgprlvkpsetlsltctvsggsisgsnyfwgwirqppgkglewigtiyyggstyynpslksrvtisvdtsenqfslklssvtaadtavyycanlawlrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsvsltisglktedeadyycqsydssnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.","VH: Chain H, WRAIR-2151 antibody Fab heavy chain / VL: Chain L, WRAIR-2151 antibody Fab light chain",2022-03-01
99,WRAIR-2125,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlslqmnslrpedtavyycakdspyyydssgyypgyfqdwgqgslvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasigdrvtitcrasqtisdylnwyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.","VH: Chain H, WRAIR-2125 antibody Fab heavy chain / VL: Chain L, WRAIR-2125 antibody Fab light chain",2022-03-01
100,WRAIR-2173,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsgdsisssdyswgwirqppgkglewigtiyyikntyynpslrsrvtlsvdtsknlfslklssvtaadtavyycarerppfdvvvvpaarpynwfdpwglgtlvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvlmqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaddeadyycqsydsslsgskvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.","VH: Chain H, WRAIR-2173 antibody Fab heavy chain / VL: Chain L, WRAIR-2173 antibody Fab light chain",2022-03-01
101,WRAIR-2057,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfisywiawvrqmpgkglewmgiiypgdsdttyspsfqgqvtisadksistaylqwsslkasdtaiyycarllyysdsspldswgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqshstprtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dussupt,V. et al.; Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations; Nat Immunol 22 (12), 1503-1514 (2021); 2021.","VH: Chain H, WRAIR-2057 Antibody Fab Heavy Chain / VL: Chain L, WRAIR-2057 Antibody Fab Light Chain",2022-03-01
102,P22A-1D1,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrdyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyyclhlnsyrtfglgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.","VH: Chain H, antibody P22A-1D1 heavy chain / VL: Chain L, antibody P22A-1D1 light chain",2022-03-01
103,P5A-3C8,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsfiysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlqehgmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkke,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqhlnsyppgytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.","VH: Chain H, antibody P5A-3C8 heavy chain / VL: Chain L, antibody P5A-3C8 light chain",2022-03-01
104,P5A-1D2,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsiiysggstyyadsvkgrftisrdnsnntlylqmnslraedtavyycaralqvgatsdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedetdyycqscdsslsvvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhang,Q. et al.; Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2; Nat Commun 12 (1), 4210 (2021); 2021.","VH: Chain B, antibody P5A-1D2 heavy chain / VL: Chain C, antibody P5A-1D2 light chain",2022-03-01
106,SARS2-38,SARS-CoV-2,Mus musculus (house mouse),qvqlkesgpglvapsqslsitctvsgfsltrygvhwvrqppgkglewlgviwadgstyynsalmsrlsiskdnsksqvflnmnslqtddtakyycardgrgyddywgqgttlt,qivltqspaimsaspgekvtmtcsasstvsfiywyqqkpgssprlliydtsnpasgvpvrfsgsgcgtsyyltisrmeaedaatyycqqwntypltfgagtklel,"VanBlargan,L. et al.; A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope; bioRxiv (2021); 2021.","VH: Chain H, SARS2-38 Fv heavy chain / VL: Chain L, SARS2-38 Fv light chain",2022-03-01
108,P2C-1A3,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardfshqqlvpswgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ge,J. et al.; Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry; Nat Commun 12 (1), 250 (2021); 2020.","VH: Chain H, antibody P2C-1A3 heavy chain / VL: Chain L, antibody P2C-1A3 light chain",2022-03-01
109,P2C-1F11,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyhcardlvvygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ge,J. et al.; Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry; Nat Commun 12 (1), 250 (2021); 2020.","VH: Chain H, antibody P2C-1F11 heavy chain / VL: Chain L, antibody P2C-1F11 light chain",2022-03-01
110,EY6A,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfssydmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggklwvyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhou,D. et al.; Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient; Nat Struct Mol Biol 27 (10), 950-958 (2020); 2020.","VH: Chain F, EY6A heavy chain / VL: Chain G, EY6A light chain",2022-03-01
122,2-36,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvsssnyywswirqppgkglewigymyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycarevyyydrsgyyasdgfdiwgqgtmvtvss,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkveik,"Wang,P. et al.; A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses; bioRxiv (2021); 2021.","VH: Chain J, 2-36 Fab heavy chain / VL: Chain K, 2-36 Fab light chain",2022-03-01
125,7D6,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgaelvrpgasvklsctasgfnikdtyihwvkqrpeqglewigridpgdgdteydpsfqgkatitadtssntaylelssltsedtavyyctrfydyvdygmdywgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkiepr,divmtqsqkfmstsvgdrvsvtckasqnvgthvawyqqkpgqspkaliysasyrysgvpdrftgsgvgtdftltitnvqsedlaeyfcqqynsyftfgsgtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnr,"Li,T. et al.; Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants; Nat Commun 12 (1), 5652 (2021); 2021.","VH: Chain C, the heavy chain of Fab fragment of antibody 7D6 / VL: Chain L, Light chain of SARS-CoV-2 cross-neutralizing mAb 6D6",2022-03-01
126,7D6,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgaelvrpgasvklsctasgfnikdtyihwvkqrpeqglewigridpgdgdteydpsfqgkatitadtssntaylelssltsedtavyyctrfydyvdygmdywgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkiepr,diqmtqspaslsasvgetvtitcrasgnihnylawyqqkqgkspqllvynaktladgvpsrfsgsgsgtqyslkinslqpedfgsyycqhfwstppwtfgggtklevkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnn,"Li,T. et al.; Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants; Nat Commun 12 (1), 5652 (2021); 2021.","VH: Chain H, the heavy chain of Fab fragment of antibody 7D6 / VL: Chain D, the light chain of Fab fragment of antibody 7D6",2022-03-01
127,CROSS-NEUTRALIZING,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgaelvkpgasvklscttsgfniidtymhwvkqrpeeglewiggidpvngnseydpkfqdkatitadtssntaylhlsrltsedtavyycasahyygssssfpywgqgtdlvtvsakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsspwpsetvtcnvahpasstkvdkkivprg,diqmtqspaslsasvgetvtitcrasgnihnylawyqqkqgkspqllvynaktladgvpsrfsgsgsgtqyslkinslqpedfgsyycqhfwstppwtfgggtklevkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnn,"Li,T. et al.; Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants; Nat Commun 12 (1), 5652 (2021); 2021.","VH: Chain H, Heavy chain of SARS-CoV-2 cross-neutralizing mAb 6D6 / VL: Chain L, the light chain of Fab fragment of antibody 7D6",2022-03-01
128,XG014,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfsnywigwvrhmpgkglewmgiiypgdsdtryspsfqgqvtisvdtsistaylqwsslkasdtamyyctrhqygynygyfyyyidvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsvltqppsvsaapgqkvtiscsgsssnignnpvswyrqvpgtapklliydnnkrpsgipdrfsgsksgasatlgitglqtgdeadyycgtwhtslssgvfgggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,Z. et al.; An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope; Protein Cell (2021) In press; 2021.","VH: Chain I, The heavy chain of XG014 / VL: Chain H, The light chain of XG014 Fab",2022-03-01
131,XG005,SARS-CoV,Homo sapiens (human),qvtlresgptlvkpkqtltltctfsgfslstpgggvgwirqppgkalewlaliywdddkryspslkssltitkdtsknqvvltmtnmdpvdtatyycarltaadtifdcwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspglsitisctatssdvgaynyvswyqqhpgqapklmiydvskrpsgvsnrfsgsksantasltisglqaedeadyycssytttsvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,Z. et al.; An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope; Protein Cell (2021) In press; 2021.","VH: Chain e, XG005 Heavy chain / VL: Chain f, XG005 Light Chain",2022-03-01
134,P5C3,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqqfqervtitrdmststaymelsslgsedtavyycaapncsggscydgfdlwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,eivltqspgtlslspgeratlscrgsqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Fenwick,C. et al.; A highly potent antibody effective against SARS-CoV-2 variants of concern; Cell Rep 37 (2), 109814 (2021); 2021.","VH: Chain I, Variable Heavy Chain P5C3 (VH) / VL: Chain L, Light ChaIn",2022-03-01
135,P5C3,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqqfqervtitrdmststaymelsslgsedtavyycaapncsggscydgfdlwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,eivltqspgtlslspgeratlscrgsqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikgtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Fenwick,C. et al.; A highly potent antibody effective against SARS-CoV-2 variants of concern; Cell Rep 37 (2), 109814 (2021); 2021.","VH: Chain F, Variable Heavy Chain P5C3 (VH) / VL: Chain H, Variable Light Chain P5C3 (VL)",2022-03-01
137,GH12-FAB,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyyctragwvrgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkththhhhhhhh,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnlwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Shi,R. et al.; A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2; Unpublished; 2021.","VH: Chain B, Heavy chain of GH12-Fab / VL: Chain C, Light chain of GH12-Fab",2022-03-01
138,N-612-004,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyymhwvrqapgkglewvsaisgsggytyyadsvkgrftisrdnskntlylqmnslraedtavyycardrdhaydwgfdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqwadwpltfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.","VH: Chain H, N-612-004 Fab heavy chain / VL: Chain L, N-612-004 Light Chain",2022-03-01
139,N-612-014,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamtwvrqapgkglewvsyisgsgggtyyadsvkgrftisrdnskntlylqmnslraedtavyycardrwasgwlafdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqayaypltfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.","VH: Chain O, N-612-014 Fab Heavy Chain / VL: Chain P, N-612-014 Light Chain",2022-03-01
142,N-612-017,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaiwgsgsntyyadsvkgrftisrdnskntlylqmnslraedtavyycargrdlaaftktafdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqhdalpwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.","VH: Chain M, N-612-017 Fab Heavy Chain / VL: Chain N, N-612-017 Light Chain",2022-03-01
144,N-612-056,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvslisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlwgsgffafdvwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqdagtpltfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tanaka,S. et al.; Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display; bioRxiv (2021); 2021.","VH: Chain C, N-612-056 Fab Heavy Chain / VL: Chain D, N-612-056 Light Chain",2022-03-01
146,2H04,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),evqlqqsgaelvkpgasvkmsckasgytftsywitwvkqrpgqglewigdiypgsgstkynekfrseatltvdtssttaymqlssltsedsavyycarwdfygsrtfdywgqgttltvssa,divltqspailsvspgervsfscrasqnigtiihwyqqrtngsprllikyasesvsgipsrfsgsgsgtdftlsinsvesediadyycqqssswpltfgagtklel,"Errico,J.M. et al.; Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD; Cell Rep 37 (4), 109881 (2021); 2021.","VH: Chain H, 2H04 heavy chain / VL: Chain L, 2H04 light chain",2022-03-01
150,2B04,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),qvqlkqsgpglvapsqslsitctvsgfslinyaiswvrqppgkglewlgviwtgggtnynsalksrlsiskdnsksqvflkmnslqtddtaryycarkdyygryygmdywgqgtsvtvs,qavvtqesalttspgetvtltcrsstgavttsnyanwvqekpdhlftgliggtnnrapgvparfsgsligdkaaltitgaqtedeaiyfcalwynnhwvfgggtkltvl,"Errico,J.M. et al.; Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD; Cell Rep 37 (4), 109881 (2021); 2021.","VH: Chain H, 2B04 heavy chain / VL: Chain L, 2B04 light chain",2022-03-01
153,C118,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycasgytgydyfvrgdyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qpvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklntdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgilvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.","VH: Chain G, C118 Fab Heavy Chain / VL: Chain L, C118 Fab Light Chain",2022-03-01
156,C022,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsvtctvsggsisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhaaayydrsgyyfieyfqhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,diqmtqspstlsasvgdsvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynnyrytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.","VH: Chain J, C022 Antibody Fab Heavy Chain / VL: Chain L, C022 Antibody Fab Light Chain",2022-03-01
160,C118,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycasgytgydyfvrgdyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,qpvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklntdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgilvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvapt,"Jette,C.A. et al.; Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies; Cell Rep 36 (13), 109760 (2021); 2021.","VH: Chain I, C118 Antibody Fab Heavy Chain / VL: Chain M, C118 Antibody Fab Light Chain",2022-03-01
162,NCOV617,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgsnkyadsvkgrftisrdnskntlylqmnslraedtavyycarglglrflewpissywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapkllifsnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslkgvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Chen,S.D. et al.; Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV617; Unpublished; 2021.","VH: Chain H, nCoV617 Heigh Chain / VL: Chain L, nCoV617 Light Chain",2022-03-01
163,58G6,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqhlewigwivvgsgntnyaqkfqervtltrdmstrtaymelsslrsedtavyycaapncnsttchdgfdiwgqgtvvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,eivltqspgtlslspgeratlscrasqsvrssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlesedfavyycqqydnspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Guo,H. et al.; Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants; Unpublished; 2021.","VH: Chain D, 58G6 heavy chain / VL: Chain E, 58G6 light chain",2022-03-01
166,13G9,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfsgsavqwvrqargqrlewigwivvgsgntnyaqrfqervtitrdmststaymelsslrsedtavyycaapycsstscrdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,eivltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Guo,H. et al.; Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants; Unpublished; 2021.","VH: Chain H, 13G9 heavy chain / VL: Chain L, 13G9 light chain",2022-03-01
169,836H,SARS-CoV-2,Homo sapiens (human),mgwslillflvavatrvlsqvqlvqsgpevkkpgtsvrvsckasgftfstsavqwvrqargqrlewigwiavgsgktdylqkfqervtmtrdestntaymqlsslrsedtavyycaaphcsggtcydgfdiwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,mgwsciilflvatatgvhseivltqspgtlslspgeratlscrasqsvrsgyfawyqqrpgraprlliygassrataipdrfsgsgsgtdftltinrlepedfavyycqqygtspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.","VH: Chain M, 836H / VL: Chain N, 836L",2022-03-01
170,BD-804H,SARS-CoV-2,Homo sapiens (human),vqlvesggglvkpggslrlscaasgftfsnydmnwvrqapgkglewvssisssstythyadsvkgrftisrdnaknslylqmnslraedtavyycardrayrlgelsslwgddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,mgwsciilflvatatgvhsdieitqspsslsasvgdrvtiscrasqdirtyvawyqqrpgkvprlliyaastlqsgvpsrfsgrgsgtdftltisslqpedvatyycqqynsapltfgggakveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.","VH: Chain H, BD-804H / VL: Chain L, 812L",2022-03-01
171,BD-771H,SARS-CoV-2,Homo sapiens (human),evqlvesgggfvkpggslrlscaasgfkfsdawmnwvrqapgkglewvgrikskadgqttdyaapvkgrfsisrddskntlflqihnlesddtavyycttgalvesryfdwftgyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,vwmtqspsllsastgdrvtvscrmsqdissylawyqqkpgkapelliyaaftlqsgvpsrfsgsgsgteftltisslqsedfatyycqqyysfphtfgqgtklerrrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.","VH: Chain H, BD-771H / VL: Chain L, BD-804L",2022-03-01
172,BD-821H,SARS-CoV-2,Homo sapiens (human),elqlvqsgaevkkpgeslkisckysgnispnfwigwvrqmagkglewmgiiypddsdsryspsfqgqviisadksittallhwsslkvsdtakyycvygsgspsnwfhpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,diqmtqspsslsasvgdrvtitcrtsqgiynylawyqqkpgkvpklliygastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkyksapltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.","VH: Chain B, BD-821H / VL: Chain L, BD-771L",2022-03-01
173,BD-667,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgfrfsdyymnwirqapgkglewisyigsggfatyygdsvkgrftvsrddaenslylqmnslraedtavyycargvtsysdnsgnyrtddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,evvmtqspatlsvspgeratlscrasqsvrynlawyqqkpgqaprlliydastratgipgrfsgsgsgteftltisslqsedfavyycqqydnwppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.","VH: Chain H, BD-667 H / VL: Chain C, BD-821L",2022-03-01
174,BD-813H,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvqpggslrlscaasefivsanymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyfcarflptydyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivmtqspatlsvspgeratlscrasqsvsrnlawyqqrpgqaprlliygastratgvaarftgsgfgteftltisglqsedfavyycqeynnwppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.","VH: Chain H, BD-813H / VL: Chain L, BD-667 L",2022-03-01
175,BD-744H,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgaswnsgtigyadsvkgrfiiirdnaknslylqmnslrsedtasyycakdfsrdgdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,yvlpqppsvsvapgktaritcggnniehksvhwyqqkprqapvvvmyydsdrpsgiperfsgsnsgntatliisrveagdeaeyycqvwdrssdqpvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Du,S. et al.; Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants; Cell Res 31 (10), 1130-1133 (2021); 2021.","VH: Chain A, BD-744H / VL: Chain B, BD-744L",2022-03-01
176,5-7,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgvinpsggstsyaekfrgrvtmtrdtststvymelsslrsedtavyycardrephsdssgywdslkyyyyyaldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthhhhhhhh,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapelliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlntypftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain; bioRxiv (2021); 2021.","VH: Chain I, 5-7 heavy chain / VL: Chain K, 5-7 light chain",2022-03-01
180,AB1,SARS-CoV-2,Homo sapiens (human),evllvesggglvqpggslrlscaasgltvssnymtwvrqapgkglewvsviysggstfyadsvkgrctisrhnskntlylqmnslraedtavyycardldyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqtgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppltfgggsrveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.","VH: Chain B, Heavy chain of Ab1 / VL: Chain C, Light chain of Ab1",2022-03-01
181,AB5,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycardrgyssgwtdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnipftfglgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.","VH: Chain B, Heavy Chain of Ab5 / VL: Chain C, Light Chain of Ab5",2022-03-01
182,AB4,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifssygmhwvrqapgkglewvaviwfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaretvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,niqmtqspsamsasvgdrvtitcrarqgisnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgseteftltisslqpedfatyyclqhnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nie,J. et al.; Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants; Cell Discov 7 (1), 53 (2021); 2021.","VH: Chain C, Heavy Chain of Ab4 / VL: Chain B, Light Chain of Ab4",2022-03-01
183,S2X259,not determined,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggifntytiswvrqapgqglewmgriilmsgmanyaqkiqgrvtitadkststaymeltslrsddtavyycargfngnyygwgdddafdiwgqgtlvtvys,qtvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapkllicgnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpnwvfgggtkltvl,"Tortorici,M.A. et al.; Broad sarbecovirus neutralization by a human monoclonal antibody; Nature 597 (7874), 103-108 (2021); 2021.","VH: Chain H, S2X259 Fab heavy chain / VL: Chain L, S2X259 Fab light chain",2022-03-01
187,C548,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarreaygprdyyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsaltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadqgsgsnfvgvfgggtkltvgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","VH: Chain O, C548 Fab Heavy Chain / VL: Chain P, C548 Fab Light Chain",2022-03-01
190,C051,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqaggslrlscaasgfgvrnnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntvflqmnslraedtavyycaregdvegfsdlwsgysrdryyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqpasvsgspgqsitfsctgtssdvggynyvswyqqypgkapklliydvtnrpsgvsdrfsgsksgntasltisglqaedeadyycssftssntrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","VH: Chain O, C051 Fab Heavy Chain / VL: Chain P, C051 Fab Light Chain",2022-03-01
193,C032,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargvavdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","VH: Chain H, C032 Fab Heavy Chain / VL: Chain L, C032 Fab Light Chain",2022-03-01
195,CR3022,SARS-CoV-2,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","VH: Chain C, CR3022 Fab heavy chain / VL: Chain D, CR3022 Fab light chain",2022-03-01
196,C099,SARS-CoV-2,Homo sapiens (human),vqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfyadsvkgrftisrddskntlflqmnslraedtaiyycardlyssggtdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,eivltqspgtlslspgeratlscrasqsigssylawyqqkpglaprlliygasrratgipdkfsgsgsgadftltisrlepedfavyycqqygsspgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrg,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","VH: Chain H, C099 Fab Heavy Chain / VL: Chain L, C099 Fab Light Chain",2022-03-01
197,C098,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlyssggtdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","VH: Chain H, C098 Fab heavy chain / VL: Chain L, C098 Fab light chain",2022-03-01
198,C032,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargvavdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","VH: Chain H, C032 Fab Heavy Chain / VL: Chain L, C032 Fab Light Chain",2022-03-01
199,C099,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfyadsvkgrftisrddskntlflqmnslraedtaiyycardlyssggtdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtlslspgeratlscrasqsigssylawyqqkpglaprlliygasrratgipdkfsgsgsgadftltisrlepedfavyycqqygsspgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","VH: Chain H, C099 Fab Heavy Chain / VL: Chain L, C099 Fab Light Chain",2022-03-01
201,C080,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslnisckasgysftiywiawvrqlpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwrslkasdsavyycargvavdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsvltqppsvsgapgqrvtiscagsssnigagfdvywyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqssgsvlsdlyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Muecksch,F. et al.; Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies; bioRxiv (2021); 2021.","VH: Chain H, C080 Fab Heavy Chain / VL: Chain L, C080 Fab Light Chain",2022-03-01
202,RBD-CHAB45,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlqqsgpelvkpgasvkiscktsgytfteytiywvkqslgkslewiggnnpnnddttykqffkgkatltvdkssstaymelrsltsedsavyycardgypyyyaldfwgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,divmtqsqkfmstsvgdrvsvtckssqnvgtnvawyqqkpgqspkaliysasyrysgvpdhftgsgsgtdftltisnvqsadlaeyfcqqynnypwtfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Su,S.C. et al.; Structure-guided antibody cocktail for prevention and treatment of COVID-19; PLoS Pathog 17 (10), e1009704 (2021); 2021.","VH: Chain H, RBD-chAb45, Heavy chain / VL: Chain L, RBD-chAb45, Light chain",2022-03-01
203,RBD-CHAB-25,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqleesggglvkpggslklscaasgftfssytmswvrqspekrlewvaeissggtytnypdtatgrftisrdnakntlylemsslrsedtamyycanfgnyeeiaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,qivltqspaimsvslgervtmtctasssvsssylhwyqqkpgsspklwiystsnlasgvparfsgsgsgtsysltissmeaedaatyychqyhrspytfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Su,S.C. et al.; Structure-guided antibody cocktail for prevention and treatment of COVID-19; PLoS Pathog 17 (10), e1009704 (2021); 2021.","VH: Chain H, RBD-chAb-25, Heavy chain / VL: Chain L, RBD-chAb-25, Light chain",2022-03-01
204,B1-182.1,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggscfdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgfpdrfsgsgsgtdftltisrlepedfavyycqqygnspwtfgqgtkveirrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants; Science 373 (6556) (2021); 2021.","VH: Chain H, B1-182.1 Fab heavy chain / VL: Chain L, B1-182.1 Fab light chain",2022-03-01
206,A23-58.1,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsnvvcydgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygtspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants; Science 373 (6556) (2021); 2021.","VH: Chain D, antibody A23-58.1 heavy chain / VL: Chain E, antibody A23-58.1 light chain",2022-03-01
210,REGN10985,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Copin,R. et al.; The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies; Cell 184 (15), 3949-3961 (2021); 2021.","VH: Chain D, REGN10985 antibody Fab fragment heavy chain / VL: Chain C, REGN10985 antibody Fab fragment light chain",2022-03-01
211,REGN10989,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Copin,R. et al.; The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies; Cell 184 (15), 3949-3961 (2021); 2021.","VH: Chain B, REGN10989 antibody Fab fragment heavy chain / VL: Chain A, REGN10989 antibody Fab fragment light chain",2022-03-01
212,S2D106,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggpfsssaiswvrqapgqglewmggiipmvgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardsrycsggscysvwfdpwgqgtlvtvss,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkvliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvemk,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.","VH: Chain H, S2D106 FAB heavy chain / VL: Chain L, S2D106 FAB light chain",2022-03-01
213,S2E12,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.","VH: Chain C, Monoclonal antibody S2E12 Fab heavy chain / VL: Chain D, Monoclonal antibody S2E12 Fab light chain",2022-03-01
214,S309,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.","VH: Chain A, Monoclonal antibody S309 Fab heavy chain / VL: Chain B, Monoclonal antibody S309 Fab light chain",2022-03-01
215,S304,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.","VH: Chain H, Monoclonal antibody S304 Fab heavy chain / VL: Chain L, Monoclonal antibody S304 Fab light chain",2022-03-01
216,S2X35,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisaykgntnyaqklqgrvtmttdtststaymelrslrsddtavyycarpdyqvlgydfwigyygmdvwgqgttvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsevvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Starr,T.N. et al.; SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape; Nature 597 (7874), 97-102 (2021); 2021.","VH: Chain H, Heavy Chain of Fab domain of monoclonal antibody S2X35 / VL: Chain L, Light Chain of Fab domain of monoclonal antibody S2X35",2022-03-01
218,S2L20,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfnsygmhwvrqapgkglewvafirydggnkyyadsvkgrftisrdnskntlylqmkslraedtavyycanlkdsrysgsyydywgqgtlvtvs,viwmtqspsslsasvgdrvtitcqasqdirfylnwyqqkpgkapkllisdasnmetgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpftfgpgtkvdf,"McCallum,M. et al.; SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern; Science 373 (6555), 648-654 (2021); 2021.","VH: Chain H, S2L20 Fab Heavy Chain Variable Region / VL: Chain L, S2L20 Fab Light Chain Variable Region",2022-03-01
220,S2M11,SARS-CoV-2,Homo sapiens (human),vqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpissgtsyaqtfqgrvtmtsdtsittaymelsrlrsddtavyycaraapfydfwsgysyfdywgqgtlvtv,ivmmqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssawtfgqgtkv,"McCallum,M. et al.; SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern; Science 373 (6555), 648-654 (2021); 2021.","VH: Chain M, S2M11 Fab Heavy Chain variable region / VL: Chain L, S2M11 Fab Light Chain variable region",2022-03-01
225,COVOX-75,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.","VH: Chain E, COVOX-75 Fab heavy chain / VL: Chain F, COVOX-75 Fab light chain",2022-03-01
226,COVOX-253,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgegatlscrasqsvsssylawyqqkpgqaprlliygassgatgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.","VH: Chain C, COVOX-253 Fab heavy chain / VL: Chain D, COVOX-253 Fab light chain",2022-03-01
233,COVOX-278,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifirygiswvrqapgqglewmgwisanngytnyaqklqgrvtmttdtststaymelrslrsddtavyycardggiltgyldyfdhwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrltitcrasqsiasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqsystlgitfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.","VH: Chain H, COVOX-278 Fab heavy chain / VL: Chain L, COVOX-278 Fab light chain",2022-03-01
234,COVOX-222,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycargegspgnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,dvvmtqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqhydtsprfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Liu,C. et al.; Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum; Cell 184 (16), 4220-4236 (2021); 2021.","VH: Chain A, COVOX-222 Fab heavy chain / VL: Chain B, COVOX-222 Fab light chain",2022-03-01
241,2B11,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaaseitvssnymnwvrqapgkglewvsviysggttyyadsvkgrftisrdnsentlylqmnslraedtavyycardlmevggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,lpvltqppsasgtpgqrvtiscsgsssnvendnvnwfqqqvpgstpklviyndrlrpsgvpdrfsgsksgtsaylaisglqsedeadyycvawdaslqsyvfgtgtkvtvlrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Pan,Y.B. et al.; Screening of potent and broadly neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries; Unpublished; 2021.","VH: Chain C, 2B11 Fab Heavy chain / VL: Chain B, 2B11 Fab Light chain",2022-03-01
243,368-2,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesgggvvqpggslrlscaasgfafttyamnwvrqapgrglewvsaisdgggsayyadsvkgrftisrdnskntlylqmnslraedtavyycaktrgrglydyvwgskdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain C, 368-2 H / VL: Chain E, L",2022-03-01
244,N9,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvkpggslrlscaaseftfssysmnwvrqapgkglewvssisssgsqiyyadsvkgrftisrdnakkslylqmnslrvedtavyycatnggahsstwsfygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngylyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain H, N9 H / VL: Chain B, 368-2 L",2022-03-01
245,368-2,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesgggvvqpggslrlscaasgfafttyamnwvrqapgrglewvsaisdgggsayyadsvkgrftisrdnskntlylqmnslraedtavyycaktrgrglydyvwgskdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvspgqtatitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltiggtqamdeaayfcqawdsntgvfgggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain a, 368-2 H / VL: Chain L, N9 L",2022-03-01
247,N9,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvkpggslrlscaaseftfssysmnwvrqapgkglewvssisssgsqiyyadsvkgrftisrdnakkslylqmnslrvedtavyycatnggahsstwsfygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvspgqtatitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltiggtqamdeaayfcqawdsntgvfgggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain S, N9 H / VL: Chain V, N9 L",2022-03-01
250,N9,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvkpggslrlscaaseftfssysmnwvrqapgkglewvssisssgsqiyyadsvkgrftisrdnakkslylqmnslrvedtavyycatnggahsstwsfygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain H, N9 H / VL: Chain P, L",2022-03-01
251,BD-515,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtgvyycardrglvsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvspgqtatitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltiggtqamdeaayfcqawdsntgvfgggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain J, BD-515 Fab Heavy Chain / VL: Chain L, N9 L",2022-03-01
252,BD-515,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtgvyycardrglvsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngylyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain G, BD-515 Fab Heavy Chain / VL: Chain J, 368-2 L",2022-03-01
254,BD-515,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtgvyycardrglvsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain A, BD-515 Fab Heavy Chain / VL: Chain E, L",2022-03-01
255,BD-508,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlflqmnslraedtavyycardaqnygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapkllifdashletgvpsrfsasgsgtdftftisslqpediatyychqydnlprtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain A, BD-508 Fab Heavy Chain / VL: Chain K, BD-515 Fab Light Chain",2022-03-01
256,BD-623,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsavysggstyyadsvkgrftisrhnskntlylqmkslrpedtaiyycarlinhyydssgdggafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapkllifdashletgvpsrfsasgsgtdftftisslqpediatyychqydnlprtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain C, BD-623 Fab H / VL: Chain H, BD-515 Fab Light Chain",2022-03-01
258,N11,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqvvqsgaevkkpgasvkvsckvsgytlieisihwvrqapgkglewmggfdpeagetiyaqkfqgrvtmtedtstdtaymevsslrsedtavyycatgpaiaaaetnwfdlwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapkllifdashletgvpsrfsasgsgtdftftisslqpediatyychqydnlprtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain M, N11 Fab heavy chain / VL: Chain B, BD-515 Fab Light Chain",2022-03-01
259,N11,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqvvqsgaevkkpgasvkvsckvsgytlieisihwvrqapgkglewmggfdpeagetiyaqkfqgrvtmtedtstdtaymevsslrsedtavyycatgpaiaaaetnwfdlwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkllifaasslqtgapsrfsgsgsgtdftltisslqpedfatyycqqsystppytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cao,Y. et al.; Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines; Cell Res 31 (7), 732-741 (2021); 2021.","VH: Chain H, N11 Fab heavy chain / VL: Chain B, BD-508 Fab Light Chain",2022-03-01
260,HB27,SARS-CoV-2,Homo sapiens (human),vklvesggglvkpggslrlscaasgftftnygmswvrqapgkrlewvaeissggsytyypdtvtgrftisrdnakntlylqmnslraedtavyycarfryggggtvdywgqgtlvtvss,ivltqsptlslspgeratlscrasesvdnygisfmnwfqqkpgqaprlliyaasnqgsgipsrfsgsgsgtdfsltisslepedfavyfcqqskevprifgqgtkveilk,"Zhu,L. et al.; Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2; Natl Sci Rev 8 (3), nwaa297 (2020); 2021.","VH: Chain I, Heavy chain of HB27 / VL: Chain H, Light chain of HB27",2022-03-01
263,HB27,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),vklvesggglvkpggslrlscaasgftftnygmswvrqapgkrlewvaeissggsytyypdtvtgrftisrdnakntlylqmnslraedtavyycarfryggggtvdywgqgtlvtvss,ivltqsptlslspgeratlscrasesvdnygisfmnwfqqkpgqaprlliyaasnqgsgipsrfsgsgsgtdfsltisslepedfavyfcqqskevprifgqgtkveilk,"Wang,X. et al.; Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27; Unpublished; 2021.","VH: Chain E, Heavy chain of HB27 / VL: Chain D, Light chain of HB27",2022-03-01
264,B6,SARS-CoV,Mus musculus (house mouse),evqlqqsgpvlvkpgasvrmsckasgytitdyylnwvkqshgkslewlgvlnpysggslysqtfkgkatltvdrssstaylelnsltsedsavyycarqlgrgngldywgqgtsvtvssvstkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,nimmtqspsslavsagekvtmsckssqsvlhssdqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvqaedlavyfchqylssytfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Sauer,M.M. et al.; Structural basis for broad coronavirus neutralization; Nat Struct Mol Biol 28 (6), 478-486 (2021); 2021.","VH: Chain H, B6 antigen binding fragment (Fab) heavy chain / VL: Chain L, B6 antigen binding fragment (Fab) light chain",2022-03-01
268,3D11,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarrwwlrgafdiwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfllyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,nfmltqphsvsaspgktvtipctgssgniasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydnniqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Asarnow,D. et al.; Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia; Cell 184 (12), 3192-3204 (2021); 2021.","VH: Chain H, Antibody Fab 3D11 heavy chain / VL: Chain L, Antibody Fab 3D11 light chain",2022-03-01
269,5A6,SARS-CoV-2,Homo sapiens (human),qvqlqesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnaknslylqmnslraedtavyycarlitmvrgedywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsslsasvghrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsynlprtfgggtklevlgtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Asarnow,D. et al.; Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia; Cell 184 (12), 3192-3204 (2021); 2021.","VH: Chain H, Antibody 5A6 Fab heavy chain / VL: Chain L, Antibody 5A6 Fab light chain",2022-03-01
272,3D11,not determined,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarrwwlrgafdiwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfllyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,nfmltqphsvsaspgktvtipctgssgniasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydnniqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Goddard,T.D. et al.; UCSF ChimeraX: Meeting modern challenges in visualization and analysis; Protein Sci 27 (1), 14-25 (2018); 2021.","VH: Chain I, Fab 3D11 heavy chain / VL: Chain N, Fab 3D11 light chain",2022-03-01
275,47D11,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsggsisshywswirqppgkglewigyiyysgstnhnpslksrvtisvdtsknqfslklssvtaadtavyycargvllwfgepifeiwgqgtmvtvss,eivmtqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliygastrapgiparfsgsgsgteftltisslqsedfavyycqqynnwpltfgggtkvei,"Fedry,J. et al.; Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11; Sci Adv 7 (23) (2021); 2021.","VH: Chain H, 47D11 neutralizing antibody heavy chain / VL: Chain L, 47D11 neutralizing antibody light chain",2022-03-01
280,CV2-75,SARS-CoV-2,Homo sapiens (human),xvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgstnynpslksrvtisvdtsknefslklssvtaadtavyycassqrpdgnlyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,syvltqppsvsvapgqtaritcggnnigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Jennewein,M.F. et al.; Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects; Cell Rep 36 (2), 109353 (2021); 2021.","VH: Chain H, CV2-75 Fab Heavy chain / VL: Chain L, CV2-75 Fab Light chain",2022-03-01
282,47D1,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvrvsckasggtfstypiswvrqapgqglewmggiipifgtaksaqkfqgrvtitadeftstaymemsslrsedtamyycaregrrygsgwyistgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qlvltqpasvsgspgqsiivsctgtssdvggykfvswyqqhpgkaprvmiydvsnrpsgvsnrfsgsksgntasltisglqaddeadyycssytnsstvvfgggtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhou,X. et al.; Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2; Cell Rep 35 (6), 109109 (2021); 2021.","VH: Chain H, 47D1 Fab heavy chain / VL: Chain L, 47D1 Fab light chain",2022-03-01
283,S2H97,SARS-CoV-2,Homo sapiens (human),qvrlvqsgaevkksgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistvylqwsslkasdtamyycarqwshytydyyywgqgtlvtissastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsvltqpasvsgspgqsitisctgissdvggynsvswyqqhpgkapklmiydvtnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstppyvfgtgtkvsvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Starr,T.N. et al.; Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape; bioRxiv (2021); 2021.","VH: Chain E, Monoclonal antibody S2H97 Fab heavy chain / VL: Chain F, Monoclonal antibody S2H97 Fab light chain",2022-03-01
284,S2X259,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggifntytiswvrqapgqglewmgriilmsgmanyaqkiqgrvtitadkststaymeltslrsddtavyycargfngnyygwgdddafdiwgqgtlvtvysastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qtvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapkllicgnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Starr,T.N. et al.; Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape; bioRxiv (2021); 2021.","VH: Chain H, Monoclonal antibody S2X259 Fab heavy chain / VL: Chain L, Monoclonal antibody S2X259 Fab light chain",2022-03-01
287,BG1-24,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriismfgiannaqkfqgrltitadtststaymelsslrsedtavyycargpyyydsggyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsvgsgylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyagsprtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","VH: Chain M, BG1-24 Fab Heavy Chain / VL: Chain N, BG1-24 Fab Light Chain",2022-03-01
289,BG7-20,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkagasvkvsckasgytftsydinwvrqasgqglewmgwmnpisgntgyaqkfqgrvtmtrntsittaymelsslrsedtavyfcarggrycssttcysgvgmdvwgqgttvtvpsastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyhqlpgtapkfliygnsnrpsgvpdrfsgsksgtsaslaitrlqaedeadyycqsydsslsgwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","VH: Chain E, BG7-20 Fab Heavy Chain / VL: Chain G, BG7-20 Fab Light Chain",2022-03-01
291,BG7-15,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyaiswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtstntaymelrslrsddtaiyycaipyssvtfdcwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsvsgtflawyqqkpgqaprllisgassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","VH: Chain R, BG7-15 Fab Heavy Chain / VL: Chain S, BG7-15 Fab Light Chain",2022-03-01
293,BG1-22,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscsvsgftvssnymnwvrqapgkglewvsviypggstfypdsvkgrftisrddskntlylqmnslrpedtaayycassrppigqlvpgldldwfdpwgqgtlvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsvsgapgqrvtisctgsssnigagyyvhwyqqhpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","VH: Chain H, BG1-22 Fab Heavy Chain / VL: Chain L, BG1-22 Fab Light Chain",2022-03-01
295,BG10-19,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgviypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycartqwgynygshffymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,qsvltqppsasgtpgqrvtiscsgsssnigsdhvywyqqlpgtapklfiyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsgyvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","VH: Chain H, BG10-19 Fab Heavy Chain / VL: Chain L, BG10-19 Fab Light Chain",2022-03-01
298,BG4-25,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvvrnymtwvrqapgkglewvsviysggttyyadsvkgrftisrdnskntmylqmnslraedtaiyycardlevvgamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkt,eivltqspgtlslspgeratlscrasqsvpssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygspmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","VH: Chain H, BG4-25 Fab Heavy Chain / VL: Chain L, BG4-25 Fab Light Chain",2022-03-01
299,CR3022,SARS-CoV-2,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Scheid,J.F. et al.; B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV; Cell 184 (12), 3205-3221 (2021); 2021.","VH: Chain A, CR3022 Fab Heavy Chain / VL: Chain B, CR3022 Fab Light Chain",2022-03-01
300,GLAMASARS-COV-2,SARS-CoV-2,synthetic construct,qvqlvetggglvqpggslrlscaasgftfssyamgwarqvpgkglewvsyiysdgsteyqdsvkgrftisrdnakstvylqmnslkpedtavyycategslggwgrdfgswgqgtqvtvssggggsggggsggggsqvqlvetgggfvqpggslrlscaasgvtldyyaigwfrqapgkeregvscigssdgrtyysdsvkgrftisrdnakntvylqmnslkpedtavyycaltvgtyysgnyhytcsddmdywgkgtqvtvssggypydvpdyaghhhhhh,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain B, SARS-CoV-2 neutralizing biparatopic nanobody VE,nanobody E from Lama glama,SARS-CoV-2 neutralizing biparatopic nanobody VE,nanobody E from Lama glama / VL: Chain L, CC12.3 Fab light chain",2022-03-01
301,CC12.3,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Koenig,P.A. et al.; Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape; Science 371 (6530) (2021); 2021.","VH: Chain H, CC12.3 Fab heavy chain / VL: Chain L, CC12.3 Fab light chain",2022-03-01
302,2-15,SARS-CoV-2,Homo sapiens (human),vqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitv,saltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvlg,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.","VH: Chain H, Fab 2-15 variable domain heavy chain / VL: Chain L, Fab 2-15 variable domain light chain",2022-03-01
303,H4,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvpycsstschrdwyfdlwgrgtlvt,diqmtqsplslpvtpgepasiscrssqslldsddgntyldwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqriefpltfgggtkvei,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.","VH: Chain H, Fab H4 variable domain heavy chain / VL: Chain L, Fab H4 variable domain light chain",2022-03-01
304,2-43,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittaymelrrlrsddtavyycarglgvgcsggncyldyyymdvwgkgttvtvss,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedegdyycssytssstwvfgggtkltvl,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Cell Rep 35 (1), 108950 (2021); 2021.","VH: Chain J, Fab 2-43 variable domain heavy chain / VL: Chain L, Fab 2-43 variable domain light chain",2022-03-01
307,2-17,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggnipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargvgyrgviplnwfdpwgqgtvvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,eivmtqspatlsvspgeratlscrasqsvssdlawyqhkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppftfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.","VH: Chain H, 2-17 Heavy Chain / VL: Chain L, 2-17 Light Chain",2022-03-01
308,5-24,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgltfssyvmhwvrqapgkgldwvgviwydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycardprdyydfwsgydyyygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,eivltqspgilslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssgaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.","VH: Chain I, 5-24 heavy chain / VL: Chain K, 5-24 light chain",2022-03-01
311,4-18,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycakdsgynygyswfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,syeltqppsvsvspgqtaritcsadalakqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdnsgtypnwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.","VH: Chain I, 4-18 heavy chain / VL: Chain K, 4-18 light chain",2022-03-01
314,1-87,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgiavigpppstyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.","VH: Chain H, 1-87 heavy chain / VL: Chain L, 1-87 light chain",2022-03-01
315,2-51,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedvetiyaqqfqgrvtmtedtstdtaymelsslrsedtavyycatgwaykstwyfgywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsrmgfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Cerutti,G. et al.; Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite; Cell Host Microbe 29 (5), 819-833 (2021); 2021.","VH: Chain C, 2-51 heavy chain / VL: Chain D, 2-51 light chain",2022-03-01
317,4-8,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkagssvkvsckasggtfsshtitwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaslqtvdtaiekyygmdvwgqgttvtvss,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Cerutti,G. et al.; Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite; Cell Host Microbe (2021); 2021.","VH: Chain Y, 4-8 Heavy Chain / VL: Chain Z, 4-8 Light chain",2022-03-01
320,2-7,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahhkierifdywgqgtlvtvss,salaqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssyttsstvfgggtkltvl,"Cerutti,G. et al.; Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies; bioRxiv (2021); 2021.","VH: Chain H, Fab 2-7 variable heavy chain / VL: Chain L, Fab 2-7 variable light chain",2022-03-01
321,1-57,SARS-CoV-2,Homo sapiens (human),evhlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddaknslylqmnslktedtavyycarvhrwaycingvcfgaysdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthhhhhhhh,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspstfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Cerutti,G. et al.; Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing Antibodies; bioRxiv (2021); 2021.","VH: Chain E, 1-57 Fab heavy chain / VL: Chain G, 1-57 Fab light chain",2022-03-01
324,DH1041,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtfssywmswvrqapgkglewvanirqdgsekysvdsvkgrftisrdnaknslylqmnslraedtavyycararradnsgyygfhfdcwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsdsksgtsaslaitrlqaedeadyycqsydsslsgwvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.","VH: Chain H, DH1041 heavy chain / VL: Chain L, DH1041 light chain",2022-03-01
325,DH1052,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgatvkisckvsgytftdyymhwvqqapgkglewmglvdpedgetiyaekfqgrvtitadtstdtaymelsslrsedtavyycatssgpsrlcgggscyhsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve,ltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqg,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.","VH: Chain H, DH1052 heavy chain / VL: Chain L, DH1052 light chain",2022-03-01
328,DH1047,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvqvscqasantftnhyihwvrqapgqglewmgiiyptggntiyaqgfqgrvtmtrdtslntiylelsslrsedtavyycardvrvddswsgydllsggtyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,divmtqspdslavslgeratincrssqsvlyssnnenylawyqqkpgqppklliywastresgipdrfsgsgsgtdftltisrlqaedvavyycqqyyslprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.","VH: Chain H, DH1047 heavy chain / VL: Chain L, DH1047 light chain",2022-03-01
331,DH1050.1,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlpelsmhwvrqapgkglewmggfhpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgspfgvvtdwfdpwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnpyvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.","VH: Chain M, DH1050.1 heavy chain / VL: Chain S, DH1050.1 light chain",2022-03-01
334,CV05-163,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarevmvrgalppygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants; Science 373 (6556), 818-823 (2021); 2021.","VH: Chain H, CV05-163 Fab heavy chain / VL: Chain L, CV05-163 Fab light chain",2022-03-01
338,MW06,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvsvisgsggstyyadsvrgrftisrdnskntlylqmnslraedtavyccakgyyydssgyyfredafdiwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsamsasvgdrvtitcrasqgisnylawfqqkpgkvpkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Jiang,W. et al.; Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV; MAbs 13 (1), 1953683 (2021); 2021.","VH: Chain J, heavy chain of MW06 / VL: Chain K, light chain of MW06",2022-03-01
342,15033-7,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfdlggysmhwvrqapgkglewvagiyasggatayadsvkgrftisadtskntaylqmnslraedtavyycarsyyyggfgmdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspsslsasvgdrvtitcrasqsvssavawyqqkpgkapklliysasdlysgvpsrfsgsrsgtdftltisslqpedfatyycqqshtypitfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Miersch,S. et al.; Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations; bioRxiv (2020); 2021.","VH: Chain J, Fab 15033-7 heavy chain / VL: Chain N, Fab 15033-7 light chain",2022-03-01
349,CR3022-B6,SARS-CoV-2,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,diqmtqspsslsasvgdrvtitcrasqsiysalnwyqqkpgkapklliyaasalqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtdihpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rouet,R. et al.; Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies; MAbs 13 (1), 1922134 (2021); 2021.","VH: Chain A, Fab heavy chain of CR3022-B6 antibody / VL: Chain B, Fab light chain of CR3022-B6 antibody",2022-03-01
350,CR3014-C8,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycargispfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscgshhhhhh,diqmtqspsslsasvgdrvtitcrasqyiydslnwyqqkpgkapklliydssylqsgvpsrfsgsgsgtdftltisslqpedfatyycqqswdtpvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Rouet,R. et al.; Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies; MAbs 13 (1), 1922134 (2021); 2021.","VH: Chain H, Fab heavy chain of CR3014-C8 antibody / VL: Chain L, Fab light chain of CR3014-C8 antibody",2022-03-01
357,LY-COV481,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycarevagtydywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpggtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.","VH: Chain A, LY-CoV481 Fab heavy chain / VL: Chain B, LY-CoV481 Fab light chain",2022-03-01
358,LY-COV488,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarspyggnswgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.","VH: Chain A, LY-CoV488 Fab heavy chain / VL: Chain B, LY-CoV488 Fab light chain",2022-03-01
359,LY-COV555,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycargyyearhyyyyyamdvwgqgtavtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhhh,diqmtqspsslsasvgdrvtitcrasqsissylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates; Sci Transl Med 13 (593) (2021); 2021.","VH: Chain D, LY-CoV555 Fab heavy chain / VL: Chain E, LY-CoV555 Fab light chain",2022-03-01
361,2G12,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkaggslilscgvsnfrisahtmnwvrrvpggglewvasistsstyrdyadavkgrftvsrddledfvylqmhkmrvedtaiyycarkgsdrlsdndpfdawgpgtvvtvspastkgpsvfplapsxxxxxxxxgtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepk,dvvmtqspstlsasvgdtititcrasqsietwlawyqqkpgkapklliykastlktgvpsrfsgsgsgteftltisglqfddfatyhcqhyagysatfgqgtrveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Acharya,P. et al.; A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies; bioRxiv (2020); 2020.","VH: Chain M, 2G12 heavy chain / VL: Chain L, 2G12 light chain",2022-03-01
369,not found,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrddskntlylqmnslraedtavyycardvadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscaaahhhhhh,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglrspvtksfnrgec,"Bertoglio,F. et al.; A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations; Biorxiv (2020); 2020.","VH: Chain H, Heavy Chain of Fab Fragment / VL: Chain L, Light Chain of Fab Fragment",2022-03-01
370,C1A-C2,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscavsgftvsnnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsafvgdrvtitcrasegissylawyqqkpgnapklliyaastlesgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.","VH: Chain H, heavy chain of human antibody C1A-C2 Fab / VL: Chain L, light chain of human antibody C1A-C2 Fab",2022-03-01
371,C1A-B3,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntvflqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.","VH: Chain H, heavy chain of antibody C1A-B3 Fab / VL: Chain L, light chain of antibody C1A-B3 Fab",2022-03-01
374,C1A-F10,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlengvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.","VH: Chain H, heavy chain of human antibody C1A-F10 Fab / VL: Chain L, light chain of human antibody C1A-F10 Fab",2022-03-01
375,C1A-B12,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggatyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlisypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.","VH: Chain H, Heavy chain of antibody C1A-B12 Fab / VL: Chain L, light chain of antibody C1A-B3 Fab",2022-03-01
378,not found,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsiiysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyycardlqelgsldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcp,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqeansfpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Guo,Y. et al.; A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes; Nat Commun 12 (1), 2623 (2021); 2020.","VH: Chain A, antibody heavy chain / VL: Chain B, antibody light chain",2022-03-01
379,S2A4,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslflqmnslraedtavyycarvwwlrgsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtc,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","VH: Chain F, S2A4 Fab heavy chain / VL: Chain G, S2A4 Fab light chain",2022-03-01
382,S2H13,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggdsvqpggslrlscaaagftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycalssgysgyagnywgqgtlvtvss,qavvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgarpedeaeyycllsysgargvfgggtkltvl,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","VH: Chain F, S2H13 Fab heavy chain / VL: Chain G, S2H13 Fab light chain",2022-03-01
385,S304,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diemtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","VH: Chain H, Heavy chain of Fab domain of monoclonal antibody S304 / VL: Chain L, Light chain of Fab domain of monoclonal antibody S304",2022-03-01
386,S2H14,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttgsetyyydssgpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","VH: Chain C, Heavy chain of Fab domain of monoclonal antibody S2H14 / VL: Chain D, Light chain of Fab domain of monoclonal antibody S2H14",2022-03-01
387,S309,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","VH: Chain A, Heavy chain of Fab domain of monoclonal antibody S309 / VL: Chain B, Light chain of Fab domain of monoclonal antibody S309",2022-03-01
388,S304,"SARS-CoV-2, Spike protein",Homo sapiens (human),vqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diemtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","VH: Chain G, S304 Fab heavy chain / VL: Chain F, S304 Fab light chain",2022-03-01
391,S2A4,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslflqmnslraedtavyycarvwwlrgsfdywgqgtlvtvss,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhvvfgggtkltvl,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell 183 (4), 1024-1042 (2020); 2020.","VH: Chain H, S2A4 Fab heavy chain / VL: Chain L, S2A4 Fab light chain",2022-03-01
396,S2X35,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisaykgntnyaqklqgrvtmttdtststaymelrslrsddtavyycarpdyqvlgydfwigyygmdvwgqgttvivssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsevvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell (2020) In press; 2020.","VH: Chain H, S2X35 antigen-binding (Fab) fragment / VL: Chain L, S2X35 antigen-binding (Fab) fragment",2022-03-01
399,S2H14,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttgsetyyydssgpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtc,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnqvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptec,"Piccoli,L. et al.; Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology; Cell (2020) In press; 2020.","VH: Chain H, S2H14 antigen-binding (Fab) fragment / VL: Chain L, S2H14 antigen-binding (Fab) fragment",2022-03-01
400,C121,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwispvsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaraplfptgvlagdyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstlvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.","VH: Chain E, C121 Fab Heavy chain / VL: Chain G, C121 Fab Light chain",2022-03-01
402,C144,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvsnnymswvrqapgkglewvsviysggstyyadsvkgrftisrdkskntlylqmnrlraedtavyycaregevegyndfwsgysrdryyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","VH: Chain O, C144 Fab Heavy Chain / VL: Chain P, C144 Fab Light Chain",2022-03-01
405,C135,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavipfdgrnkyyadsvtgrftisrdnskntlylqmnslraedtavyycasssgylfhsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasvgdrvtitcrasqsisnwlawfqqkpgkapklliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","VH: Chain M, C135 Fab Heavy Chain / VL: Chain N, C135 Fab Light Chain",2022-03-01
408,C119,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqklqgrvtmtrdtststvymelsslrsedtavyycaranhettmdtyyyyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqpasvsgspgqsitisctgtssdvggykyvswyqrhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstsvvfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","VH: Chain N, C119 Fab Heavy Chain / VL: Chain S, C119 Fab Light Chain",2022-03-01
410,C110,SARS-CoV-2,Homo sapiens (human),qvqlqqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaymqwsslkasdtamyycarsfrddpriavagpadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasvgdrvtitcrasqsisywlawyqqkpgkapklliyqasslesgvpsrfsgsesgteftltisslqpddfatyycqqynsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","VH: Chain M, C110 Fab Heavy Chain / VL: Chain N, C110 Fab Light Chain",2022-03-01
412,C104,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlslscavyggslsgyywswirqppgkglewigeinhfgstgynpslksrvtisvdtsksqfsvklssvtaadtavyycarkpllysnlspgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtvslspgeratlscwasqsvsasylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygttprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","VH: Chain H, C104 Fab Heavy Chain / VL: Chain L, C104 Fab Light Chain",2022-03-01
413,C002,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakegrpsdivvvvafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","VH: Chain O, C002 Fab Heavy Chain / VL: Chain P, C002 Fab Light Chain",2022-03-01
419,C102,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.","VH: Chain A, C102 Fab Heavy Chain / VL: Chain B, C102 Fab Light Chain",2022-03-01
420,C135,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavipfdgrnkyyadsvtgrftisrdnskntlylqmnslraedtavyycasssgylfhsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,diqmtqspstlsasvgdrvtitcrasqsisnwlawfqqkpgkapklliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature 588 (7839), 682-687 (2020); 2020.","VH: Chain H, C135 Fab Heavy Chain / VL: Chain L, C135 Fab Light Chain",2022-03-01
422,C110,SARS-CoV-2,Homo sapiens (human),qvqlqqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaymqwsslkasdtamyycarsfrddpriavagpadafdiwgqgtmvtvssastkgpsvfplapsskstsgptaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,diqmtqspstlsasvgdrvtitcrasqsisywlawyqqkpgkapklliyqasslesgvpsrfsgsesgteftltisslqpddfatyycqqynsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","VH: Chain H, C110 Fab Heavy Chain / VL: Chain L, C110 Fab Light Chain",2022-03-01
424,C102,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapssksxxxxtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepk,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Barnes,C.O. et al.; SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies; Nature (2020) In press; 2020.","VH: Chain A, C102 Fab Heavy Chain / VL: Chain B, C102 Fab Light Chain",2022-03-01
425,S2E12,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvss,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveik,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science 370 (6519), 950-957 (2020); 2020.","VH: Chain F, S2E12 neutralizing antibody Fab fragment (heavy chain) / VL: Chain G, S2E12 neutralizing antibody Fab fragment (light chain)",2022-03-01
429,S2M11,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpissgtsyaqtfqgrvtmtsdtsittaymelsrlrsddtavyycaraapfydfwsgysyfdywgqgtlvtvss,eivmmqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssawtfgqgtkveik,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science 370 (6519), 950-957 (2020); 2020.","VH: Chain F, S2M11 Fab fragment (heavy chain) / VL: Chain G, S2M11 Fab fragment (light chain)",2022-03-01
432,S2E12,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvrvsckasgftftssavqwvrqargqrlewvgwivvgsgntnyaqkfhervtitrdmststaymelsslrsedtavyycaspycsggscsdgfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divltqtpgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvgltgwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Tortorici,M.A. et al.; Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms; Science (2020) In press; 2020.","VH: Chain H, Fab fragment of S2E12 monoclonal antibody, heavy chain / VL: Chain L, Fab fragment of S2E12 monoclonal antibody, light chain",2022-03-01
433,COVA2-04,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardleraggmdvwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygslytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wu,N.C. et al.; An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain; Cell Rep 33 (3), 108274 (2020); 2020.","VH: Chain H, COVA2-04 heavy chain / VL: Chain L, COVA2-04 light chain",2022-03-01
434,COVA2-39,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviytggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarahvdtamvesgafdiwgqgtrvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkschhhhhh,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wu,N.C. et al.; An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain; Cell Rep 33 (3), 108274 (2020); 2020.","VH: Chain H, COVA2-39 heavy chain / VL: Chain L, COVA2-39 light chain",2022-03-01
435,CC12.3,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; Structural basis of a public antibody response to SARS-CoV-2; bioRxiv (2020); 2020.","VH: Chain C, CC12.3 heavy chain / VL: Chain D, CC12.3 light chain",2022-03-01
439,CC12.1,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; Structural basis of a public antibody response to SARS-CoV-2; bioRxiv (2020); 2020.","VH: Chain X, CC12.1 heavy chain / VL: Chain Y, CC12.1 light chain",2022-03-01
443,G2,MERS-CoV,Mus musculus (house mouse),qvqlqqsggelvkpgasvklscktsgftfsssyiswlkqkpgqslewiawiyagtggteynqkftgkaqvtvdtssstaymqfsslttedsaiyycarggssfamdywgqgtsvtvssasttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgkglevlfq,qlvltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllihtasnqgsgvparfsgsgsgtdfslnihpvedddtamyfcqqseevpltfgagtkleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,N. et al.; Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD; Cell Rep 28 (13), 3395-3405 (2019); 2019.","VH: Chain H, G2 heavy chain / VL: Chain L, G2 light chain",2022-03-01
452,G4,MERS-CoV,Mus musculus (house mouse),qvqlqqsgpelvrpgvsvkisckgsgytftdyaihwvkqshakslewigvfstyygntnynqkfkgratmtvdkssstaymelarltsedsaiyycarksyyvdyvdamdywgqgtsvtvssasttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgkglevlfq,divltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllisatsnqgsgvparfigsgsgtdfslnihpveeddtamyfcqqskevprtfgggtkleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Pallesen,J. et al.; Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen; Proc Natl Acad Sci U S A 114 (35), E7348-E7357 (2017); 2017.","VH: Chain H, G4 VH / VL: Chain I, G4 VL",2022-03-01
476,G4,MERS-CoV,Mus musculus (house mouse),xvqlqqsgpelvrpgvsvkisckgsgytftdyaihwvkqshakslewigvfstyygntnynqkfkgratmtvdkssstaymelarltsedsaiyycarksyyvdyvdamdywgqgtsvtvssasttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgkglevlfq,divltqspaslavslgqratiscrasesvdnygisfmnwfqqkpgqppkllisatsnqgsgvparfigsgsgtdfslnihpveeddtamyfcqqskevprtfgggtkleikrtdaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Pallesen,J. et al.; Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen; Proc Natl Acad Sci U S A 114 (35), E7348-E7357 (2017); 2017.","VH: Chain A, G4 antibody heavy chain / VL: Chain B, G4 antibody light chain",2022-03-01
478,S3H3,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),qvqlqqpgaelvrpgasvklsckasgysftrfwmnwvkqrpgqglewigmihpsdsetrlnqkfkdkatltvdkssttaymqlssptsedsavyycarkdydydawfaywgqgtlvtvsaakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,divltqspaslavslgqratiscrasksvsasvysymhwyqqkpgqppklliylasslesgvparfsgsgsgtdftlnihpveeedaatyychhsrelppafgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnr,"Xu,S. et al.; Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein; Emerg Microbes Infect 11 (1), 351-367 (2022); 2022.","VH: Chain F, Heavy chain of S3H3 Fab / VL: Chain G, Light chain of S3H3 Fab",2022-03-01
484,S5D2,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgqslewigginpniddttynqnfkdkatltvdkssstaymefrsltfddsavyycarddkasfafwgqgtlvtvsaakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,divmsqspsslavsdgervtltckssqsllystnqknylawyqqkpgqspklliywassresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypltfgagtklelradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Xu,S. et al.; Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein; Emerg Microbes Infect 11 (1), 351-367 (2022); 2022.","VH: Chain e, Heavy chain of S5D2 Fab / VL: Chain f, Light chain of S5D2 Fab",2022-03-01
491,R40-1G8,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymrwvrqapgkglewvsliyaggstfyadsvkgrfiisrhnsknilylqmnslraedtavyfcardlyvfgmdvwgqgtavtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkth,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgrapklliyaastlqsgvpsrfsgsgsgtvftltisslqpedfatyycqqlnsdsstfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe 30 (1), 69-82 (2022); 2022.","VH: Chain P, R40-1G8 Fab heavy chain / VL: Chain Q, R40-1G8 Fab light chain",2022-03-01
494,COVOX-158,not determined,Homo sapiens (human),evqllesggdliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiypggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardlgsgdmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliqaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyrytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.","VH: Chain H, COVOX-158 heavy chain / VL: Chain L, COVOX-158 light chain",2022-03-01
495,COVOX-58,not determined,Homo sapiens (human),qvqlvesggglvqpgrslrlscaasgftfddyamhwvrqppgkglewvsgvswnsgtigyadsvkgrfiisrdnaknslylqmnslkaedtalyycarevggtfgvlisreggldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,syeltqppsvsvapgqtaritcggntigsksvhwyqqrpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdrvvfgggtkltvlgqpkaaptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.","VH: Chain A, COVOX-58 heavy chain / VL: Chain B, COVOX-58 light chain",2022-03-01
496,BETA-55,not determined,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsisssryywgwirqppgkglewigtfyysgityynpslksrvtifvdtsknqfslklssvtaadtavyycarprppdyydnsgallfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,airmtqspstlsasvgdrvtiacrasqsisawlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltinslqpddfatyycqqyissspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.","VH: Chain A, Beta-55 heavy chain / VL: Chain B, Beta-55 light chain",2022-03-01
497,EY6A,not determined,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfssydmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggklwvyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlaltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses; bioRxiv (2021); 2022.","VH: Chain H, EY6A heavy chain / VL: Chain L, EY6A light chain",2022-03-01
500,C1C-A3,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),mkrglccvlllcgavfvspsasqvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgtntyyadsvkgrftisrdnskntlylqmnslraedtavyycardlayrdyvwryfdlwgrgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,mkrglccvlllcgavfvspsaseivltqspatlslspgeratlscrasqsvstylawyqqkfgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqcrsnwppgitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Nabel,K.G. et al.; Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain; Science 375 (6578), eabl6251 (2022); 2021.","VH: Chain H, neutralizing antibody C1C-A3 heavy chain variable region / VL: Chain L, neutralizing antibody C1C-A3 light chain variable region",2022-03-01
505,AB8,"SARS-CoV-2, Spike protein",synthetic construct,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvsssgqaghhhhhhgdykddddkg,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.","VH: Chain E, VH ab8 / VL: Chain I, Fab ab1 Light Chain",2022-03-01
509,AB1,"SARS-CoV-2, Spike protein",synthetic construct,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsgqaghhhhhhgdykddddkg,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.","VH: Chain H, Fab ab1 Heavy Chain / VL: Chain E, Fab ab1 Light Chain",2022-03-01
511,CA521,SARS-CoV-2,Homo sapiens (human),evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigevnhsgstnynpslksrvtisvdtsknqlslklnsvtaadtavyycargntmvrgviipfeywdkgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslg,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Song,D. et al.; Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2; Commun Biol 4 (1), 500 (2021); 2021.","VH: Chain B, CA521 Heavy Chain / VL: Chain C, CA521 Light Chain",2022-03-01
512,P008_056,SARS-CoV-2,Homo sapiens (human),mgwsciilflvatatgvhsevqlvesggglvkpggslrlscaasgfsfssysmnwvrqapgkglewvssissnsnyiyyadsmkgrftisrdnaknslylqmnslraedtavyycasnrspydssnyyfdywgqgtrvtissastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksgtkhhhhhh,mgwsciilflvatatgvhcairmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqhhdslpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Rosa,A. et al.; SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity; Sci Adv (2021) In press; 2021.","VH: Chain H, P008_056 Fab Heavy chain / VL: Chain L, P008_056 Fab Light chain",2022-03-01
513,FC08,SARS-CoV-2,Homo sapiens (human),qllqqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipiigianyaqkfqgrvtitadkststaymelsslrsedtavyycarergysgygaayyfdywgqgtlvtvssa,svltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvlgq,"Zhang,L. et al.; A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2; Natl Sci Rev 8 (8), nwab053 (2021); 2021.","VH: Chain H, Heavy chain of FC08 Fab / VL: Chain L, Light chain of FC08 Fab",2022-03-01
514,FC05,SARS-CoV-2,Homo sapiens (human),evqlleqsgaevkkpgasvrvsckvsgytlpevamhwvrqapgkglewmggfdpedgetmyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatttpfsssywfdpwgqgtlvtvss,qsvltqapsvsgapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,"Zhang,L. et al.; A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2; Natl Sci Rev 8 (8), nwab053 (2021); 2021.","VH: Chain N, Heavy chain of FC05 Fab / VL: Chain G, Light chain of FC05 Fab",2022-03-01
515,S2M28,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvtviwydgsnryyadsvkgrftisrdnskntlylqmdslraedtavyycaravagewyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,syeltqppsvsvspgqtaritcsgdalakhyaywyrqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsigsswvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvapte,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.","VH: Chain F, S2M28 Fab Heavy Chain / VL: Chain E, S2M28 Fab Light Chain",2022-03-01
517,S2M28,SARS-CoV-2,Homo sapiens (human),vqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvtviwydgsnryyadsvkgrftisrdnskntlylqmdslraedtavyycaravagewyfdywgqgtlvtvs,yeltqppsvsvspgqtaritcsgdalakhyaywyrqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsigsswvfgggtkltv,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.","VH: Chain N, S2M28 Fab Heavy Chain variable region / VL: Chain O, S2M28 Fab Light Chain variable region",2022-03-01
524,S2L28,SARS-CoV-2,Homo sapiens (human),evqlvesggglvnpggslrlscaasgftfsdytihwvrqapgkglewvssissssnyiyyadsvkgrftisrdnaknslslqmnslraedtavyycardgnaykwllaenvrfdywgqgtlvtvss,vtqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsdrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpnwvfgggtklt,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.","VH: Chain N, S2L28 Fab Heavy Chain variable region / VL: Chain O, S2L28 Fab Light Chain variable region",2022-03-01
530,S2X333,SARS-CoV-2,Homo sapiens (human),vqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnsknslylqmnslraedtavyfcarafpdssswsgftidywgqgtlvtv,yeltqppsvstaritcggnnierksvhwcqqkpgqapalvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdqvifgggtklt,"McCallum,M. et al.; N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2; Cell (2021) In press; 2021.","VH: Chain N, S2X333 Fab Heavy Chain variable region / VL: Chain O, S2X333 Fab Light Chain variable region",2022-03-01
550,DH1043,SARS-CoV-2,Homo sapiens (human),mgwsciilflvatatgvhsqvqlvqsgaevkkpgssvkvsckasggtfsryainwvrqapgqglewmgriipifgianyaqkfqgkvtitadkststaymelsslrsedtavyycaradyyydssgyffdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvlhealhshytqkslslspgk,mgwsciilflvatatgvhseivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqtprlliygassratgiparfsgsgsgtnftltisrlepedfavyycqqysssrtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,D. et al.; The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates; bioRxiv (2021); 2021.","VH: Chain S, Fab DH1043 heavy chain / VL: Chain T, Fab DH1043 light chain",2022-03-01
551,H11-H4,"SARS-CoV-2, Spike protein RBD",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycaqthyvsyllsdyatwpydywgqgtqvtvsskhhhhhh,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrge,"Huo,J. et al.; Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2; Nat Struct Mol Biol 27 (9), 846-854 (2020); 2021.","VH: Chain FFF, Nanobody H11-H4 / VL: Chain LLL, CR3022 Light chain",2022-03-01
552,P5A-3C12,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahslfltvgyssswspfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkve,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystphtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","VH: Chain G, Heavy chain of P5A-3C12 / VL: Chain F, Light chain of P5A-3C12",2022-03-01
554,P5A-3A1,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardygdfyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","VH: Chain G, Heavy chain of P5A-3A1 / VL: Chain F, Light chain of P5A-3A1",2022-03-01
557,4-61CHAIN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsvssgsyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarercyygsgraprcvwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","VH: Chain H, Immunoglobulin heavy variable 4-61,chain H of FabP5A-2G7,Epididymis luminal protein 214 / VL: Chain L, IGL c2312_light_IGLV2-14_IGLJ2,IGL@ protein",2022-03-01
558,C642_HEAVY_IGHV3-53_IGHD1-26_IGHJ6CHAIN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","VH: Chain J, IG c642_heavy_IGHV3-53_IGHD1-26_IGHJ6,chain H of FabP5A-1B8,IGH@ protein / VL: Chain N, IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",2022-03-01
560,1-8IMMUNOGLOBULIN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycaryivvvpaakgfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","VH: Chain J, Immunoglobulin heavy variable 1-8,Immunoglobulin heavy variable 1-8,chain H of P5A-2F11_3B,Epididymis luminal protein 214,Epididymis luminal protein 214 / VL: Chain N, IG c168_light_IGKV4-1_IGKJ4,Immunoglobulin kappa constant",2022-03-01
565,4-59CHAIN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyisysgstnynpslksrvtisldtsknqfslklssvtaadtavyycasngqyydiltgqppdywyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","VH: Chain J, Immunoglobulin heavy variable 4-59,chain H of P5A-1B9,IGH@ protein / VL: Chain N, IG c168_light_IGKV4-1_IGKJ4,Uncharacterized protein",2022-03-01
570,3-30-3CHAIN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqaitmvqgvigppfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","VH: Chain J, Immunoglobulin heavy variable 3-30-3,chain H of P5A-1B6_3B,Immunoglobulin gamma-1 heavy chain / VL: Chain N, Immunoglobulin kappa variable 1-33,Uncharacterized protein",2022-03-01
573,3-30-3IMMUNOGLOBULIN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqaitmvqgvigppfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","VH: Chain H, Immunoglobulin heavy variable 3-30-3,Immunoglobulin heavy variable 3-30-3,Chain H of P5A-1B6_2B,Immunoglobulin gamma-1 heavy chain,Immunoglobulin gamma-1 heavy chain / VL: Chain K, Immunoglobulin kappa variable 1-33,Immunoglobulin kappa variable 1-33,Uncharacterized protein",2022-03-01
575,3-33CHAINH,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarwfhtggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qpvltqppsssaspgesarltctlpsdinvssyniywyqqkpgsppryllyyysdsdkgqgsgvpsrfsgskdasantgillisglqsedeadyycmiwpsnalyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","VH: Chain I, Immunoglobulin heavy variable 3-33,chainH of P5A-2G9,Immunoglobulin gamma-1 heavy chain / VL: Chain M, IG c689_light_IGLV5-37_IGLJ3,IGL@ protein",2022-03-01
577,C542_HEAVY_IGHV3-53_IGHD3-10_IGHJ6IGH@,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaretlafdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","VH: Chain J, IG c542_heavy_IGHV3-53_IGHD3-10_IGHJ6,IGH@ protein / VL: Chain N, IGL c4203_light_IGKV1-9_IGKJ4,Uncharacterized protein",2022-03-01
582,C642_HEAVY_IGHV3-53_IGHD1-26_IGHJ6CHAIN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaregpksitgtafdiwgqgtivtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcqasqdisnyfnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","VH: Chain J, IG c642_heavy_IGHV3-53_IGHD1-26_IGHJ6,Chain H of P2B-1A10,Immunoglobulin gamma-1 heavy chain / VL: Chain N, Immunoglobulin kappa variable 1-33,Uncharacterized protein",2022-03-01
584,4-59CHAIN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtskkqfslklssvtaadtavyycarlerdwpldafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapkfmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsnntfafgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Yan,R. et al.; Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies; Cell Res 31 (5), 517-525 (2021); 2021.","VH: Chain J, Immunoglobulin heavy variable 4-59,Chain H of P2B-1A1,Anti-RhD monoclonal T125 gamma1 heavy chain / VL: Chain N, IG c181_light_IGLV2-14_IGLJ3,IGL@ protein",2022-03-01
586,COVOX-269,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgltvnrnymswirqapgkglewvsviysggstfyadsvkgrftisrdnskntlslqmnslraedtaiyycardfyegsfdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,aiqltqspsflsasigdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfasyycqqlnsypapvfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Supasa,P. et al.; Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera; Cell 184 (8), 2201-2211 (2021); 2021.","VH: Chain H, COVOX-269 Fab heavy chain / VL: Chain L, COVOX-269 fab light chain",2022-03-01
588,COVOX-159,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsevqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydggnryyadsvkgrftisrdnskntlylqmnrlraedtamyycakdrddgwdwyyfmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspgtlslspgeratlscrasqsisgnylawyqhkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain H, COVOX-159 Fab heavy chain / VL: Chain L, COVOX-159 Fab light chain",2022-03-01
594,COVOX-253H165L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygasrrgtgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain H, COVOX-253H165L Fab heavy chain / VL: Chain L, COVOX-253H165L Fab light chain",2022-03-01
595,COVOX-253H55L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain H, COVOX-253H55L Fab heavy chain / VL: Chain L, COVOX-253H55L Fab light chain",2022-03-01
597,COVOX-384,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsevqlvesggglvkpgeslrlscaasgftfsdyymtwirqapgkglewvsyirssghtiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarggvlrflewplnafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynnalgtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain H, COVOX-384 Fab heavy chain / VL: Chain L, COVOX-384 Fab light chain",2022-03-01
598,COVOX-316,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqkfqgrvtmtrdtsistaymelsrlrsddtavyscardmafsmvrgsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qavltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnhwvfgggtkltvlgqpkaaptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain J, COVOX-316 Fab heavy chain / VL: Chain K, COVOX-316 Fab light chain",2022-03-01
601,COVOX-158,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqllesggdliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiypggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardlgsgdmdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliqaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyrytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain H, COVOX-158 Fab heavy chain / VL: Chain L, COVOX-158 Fab light chain",2022-03-01
602,COVOX-150,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsiiysggttyyadsvkgrftisrdssmntlylqmnslraedtavyycardlmvygidvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhseivmtqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqldsyppgytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain H, COVOX-150 Fab heavy chain / VL: Chain L, COVOX-150 Fab light chain",2022-03-01
603,COVOX-88,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqlqlqesgpglvkpsqtlsltctvsggsissgsynwtwirqpagkglewigriynsgstnynpslksrvtisvdtsknqlslkvrsvtaadtavyycarhcsggtcypkyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgswaqsaltqppsvseaprqrvtiscsgsssnignnavnwyqqfpgkapklliyyddllpsgvsdrfsgsksgtsaslaisgvqsedeadyycaawddslnvvvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain F, COVOX-88 Fab heavy chain / VL: Chain G, COVOX-88 Fab light chain",2022-03-01
606,COVOX-40,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvesggglvqpggslrlscavsgftvsrnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlfhrsgyhdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsviwmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapkllifdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpafgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain H, COVOX-40 heavy chain / VL: Chain L, COVOX-40 light chain",2022-03-01
607,S309,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain G, S309 heavy chain / VL: Chain I, S309 light chain",2022-03-01
611,COVOX-75,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain E, COVOX-75 heavy chain / VL: Chain F, COVOX-75 light chain",2022-03-01
612,COVOX-253H55L,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain C, COVOX-253H55L heavy chain / VL: Chain D, COVOX-253H55L light chain",2022-03-01
615,COVOX-75,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnnyplhwvrqapgkgpewvavisqdggnkyyvdsvkgrftisrdnskntlylqmnnlraedtalyycardvvvvvaarnhyyngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfpftfgpgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain G, COVOX-75 heavy chain / VL: Chain I, COVOX-75 light chain",2022-03-01
616,COVOX-253,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstttaymelsslrsedtavyfcaaphcnstscydafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqmtqspgtlslspgegatlscrasqsvsssylawyqqkpgqaprlliygassgatgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain D, COVOX-253 heavy chain / VL: Chain F, COVOX-253 light chain",2022-03-01
619,COVOX-269,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgltvnrnymswirqapgkglewvsviysggstfyadsvkgrftisrdnskntlslqmnslraedtaiyycardfyegsfdiwgqgtmvtvssastggsggggsggggsgg,gasaiqltqspsflsasigdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfasyycqqlnsypapvfgpgtkvdikaaalvprgssawshpqfekggsgggsggsawshpqfek,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain H, COVOX-269 Vh domain / VL: Chain L, COVOX-269 Vl domain",2022-03-01
620,COVOX-88,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqlqlqesgpglvkpsqtlsltctvsggsissgsynwtwirqpagkglewigriynsgstnynpslksrvtisvdtsknqlslkvrsvtaadtavyycarhcsggtcypkyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsdiqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftitslqpediatyycqqydnlpltfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain E, COVOX-88 heavy chain / VL: Chain D, COVOX-45 light chain",2022-03-01
621,COVOX-45,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggsyayyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgswaqsaltqppsvseaprqrvtiscsgsssnignnavnwyqqfpgkapklliyyddllpsgvsdrfsgsksgtsaslaisgvqsedeadyycaawddslnvvvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain C, COVOX-45 heavy chain / VL: Chain F, COVOX-88 light chain",2022-03-01
627,COVOX-316,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),ilflvatatgvhsqvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqkfqgrvtmtrdtsistaymelsrlrsddtavyscardmafsmvrgsfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,ilflvatatgvhsqavltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnhwvfgggtkltvlgqpkaaptvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Dejnirattisai,W. et al.; The antigenic anatomy of SARS-CoV-2 receptor binding domain; Cell 184 (8), 2183-2200 (2021); 2021.","VH: Chain H, COVOX-316 heavy chain / VL: Chain L, COVOX-316 light chain",2022-03-01
628,H014,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleilkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsesvteqdskdstyslsstltlskadyekhkvyacevthqglsstksfnrgec,"Lv,Z. et al.; Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody; Science 369 (6510), 1505-1509 (2020); 2021.","VH: Chain E, Heavy chain of H014 Fab / VL: Chain D, Light chain of H014 Fab",2022-03-01
634,H014,SARS-CoV-2,Homo sapiens (human),vqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleil,"Lv,Z. et al.; Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody; Science 369 (6510), 1505-1509 (2020); 2020.","VH: Chain E, Heavy chain of H014 Fab / VL: Chain D, Light chain of H014 Fab",2022-03-01
635,S304,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglewvstigtagdtyypdsvkgrftisredaknslylqmnslragdtavyycargdssgyyyyfdywgqgtlltvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqmtqspsslsaavgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqqsyvsptytfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Thomson,E.C. et al.; Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity; Cell 184 (5), 1171-1187 (2021); 2021.","VH: Chain M, Monoclonal antibody S304 Fab heavy chain / VL: Chain N, Monoclonal antibody S304 Fab light chain",2022-03-01
639,2-15,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkv,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Rapp,M. et al.; Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class; Biorxiv (2021); 2021.","VH: Chain H, 2-15 Heavy chain / VL: Chain L, 2-15 Light Chain",2022-03-01
640,910-30,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycariygdyawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsrsgtdftftisslqpediatyychqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Banach,B.B. et al.; Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses; bioRxiv (2021); 2021.","VH: Chain H, 910-30 Fab heavy chain / VL: Chain L, 910-30 Fab light chain",2022-03-01
641,LY-COV555,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycargyyearhyyyyyamdvwgqgtavtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrvhhhhh,diqmtqspsslsasvgdrvtitcrasqsissylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevtqgttsvtksfnrgec,"Jones,B.E. et al.; LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection; bioRxiv (2020); 2021.","VH: Chain D, LY-CoV555 Fab heavy chain / VL: Chain E, LY-CoV555 Fab light chain",2022-03-01
642,P17,SARS-CoV,Homo sapiens (human),qqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarhatlmnnkdiwgqgtlvtvssas,gdiqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res 31 (1), 25-36 (2021); 2021.","VH: Chain I, Fab P17 heavy chain / VL: Chain K, Fab P17 light chain",2022-03-01
646,H014,SARS-CoV,Homo sapiens (human),vqlvqsgaevkkpgatvkisckvsgysfsnyyihwvkqapgkslewigyidpfnggtsdnlkfkgaatltadtstdtaymelsslrsedtavyycarseydpyyvmdywgqgttvtvssastkgpsvfplapsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,ivltqspfqsvspkekvtitcrasqsissnlhwyqqkpdqspkllikyasqsisgipsrfsgsgsgtdftltinsleaedfgiyfcqqtnfwpyifgqgtkleilkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsesvteqdskdstyslsstltlskadyekhkvyacevthqglsstksfnr,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res (2020) In press; 2020.","VH: Chain O, heavy chain of H014 Fab / VL: Chain M, light chain of H014 Fab",2022-03-01
647,P17,SARS-CoV,Homo sapiens (human),qqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarhatlmnnkdiwgqgtlvtvssastkgpsvfplapsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,gdiqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsesvteqdskdstyslsstltlskadyekhkvyacevthqglsstksfnr,"Yao,H. et al.; Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection; Cell Res (2020) In press; 2020.","VH: Chain G, heavy chain of P17 Fab / VL: Chain F, light chain of P17 Fab",2022-03-01
655,not found,not determined,Homo sapiens (human),qitlkesgptlvkptqtltltcsfsgfslstsgvgvgwirqppgkalewlalidwddnkyhttslktrltiskdtsknqvvltmtnmdpvdtatyycaripgflryrnryyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,elvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggteltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kim,Y.G. et al.; to be publish; Unpublished; 2021.","VH: Chain H, IgG heavy chain / VL: Chain L, IgG light chain",2022-03-01
656,2H2,SARS-CoV-2,Mus musculus (house mouse),qvqlkqsgpslvqpsqslsitctvsgfsltsygvhwvrqspgkglewlgvmwrggntdynaafmsrlsitkdnsksqvffkmnslqtddtaiyycaknggahamdfwgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkki,nivltqspaslavslgqratiscrasesvdsygnsflhwyqqkpgqppklliylasnlesgvparfsgsgsrtdftltidpveaddaatyycqqnnedpftfgsgtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.","VH: Chain c, The heavy chain fragment of 2H2 Fab / VL: Chain d, The light chain fragment of 2H2 Fab",2022-03-01
665,3C1,SARS-CoV-2,Mus musculus (house mouse),evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcg,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.","VH: Chain A, The heavy chain of 3C1 fab / VL: Chain B, The light chain of 3C1 chain",2022-03-01
668,3C1,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcg,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Zhang,C. et al.; Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections; Nat Commun 12 (1), 264 (2021); 2020.","VH: Chain E, The heavy chain of 3C1 fab that binds with the up RBD / VL: Chain H, The light chain of 3C1 fab",2022-03-01
674,CV07-250,SARS-CoV-2,Homo sapiens (human),qvqlvqseaevkepgasvevsckasgynftnfaiswvrqapgqglewmgwisgyngdtnsaqkflgrvtmttdtstttaymelrslrsddtavyycagsdnygfpyngmdvwgqgttvtvfnqikppsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsaltqppsasgspgqsvtisctgtssdlgayhfvtwyqhypgkapkvmiygvrkrpsgvpdrfsgsksgntasltvsglqdedeadyycssyagnndfvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell(Cambridge,Mass.) (2020); 2020.","VH: Chain H, CV07-250 Heavy Chain / VL: Chain L, CV07-250 Light Chain",2022-03-01
675,CV07-270,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymtwirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarargssgwyrigtrwgnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssnvvfgggtmltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell(Cambridge,Mass.) (2020); 2020.","VH: Chain M, CV07-270 Heavy Chain / VL: Chain N, CV07-270 Light Chain",2022-03-01
677,BD-368-2,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpggslrlscaasgfafttyamnwvrqapgrglewvsaisdgggsayyadsvkgrftisrdnskntlylqmnslraedtavyycaktrgrglydyvwgskdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell (2020) In press; 2020.","VH: Chain J, BD-368-2 Fab heavy chain / VL: Chain K, BD-368-2 Fab light chain",2022-03-01
681,BD-604,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmsslraedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,diqltqspsflsasvgdrvtitcrasqgissdlawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdlytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.","VH: Chain H, BD-604 Fab heavy chain / VL: Chain L, BD-604 Fab light chain",2022-03-01
683,BD-236,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstdyadsvkgrftisrdkskntlylqmnslraedtavyycardlgeaggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsyppafgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.","VH: Chain H, BD-236 Fab heavy chain / VL: Chain L, BD-236 Fab light chain",2022-03-01
685,BD-629,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlnlqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,eivltqspgtlslspgeratlscrasqgvssflawyqqkpgqaprllihgassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.","VH: Chain H, BD-629 Fab H / VL: Chain L, IGK@ protein",2022-03-01
689,2-4,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqmfqgrvtmtrdtsistaymevsrlrsddtavyycardrswavvyyymdvwgkgttvtvss,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,"Liu,L. et al.; Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike; bioRxiv (2020); 2020.","VH: Chain J, 2-4 Heavy Chain / VL: Chain L, 2-4 Light Chain",2022-03-01
692,4A8,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetmyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatstavagtpdlfdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,eivmtqsplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfpytfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Chi,X. et al.; A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2; Science 369 (6504), 650-655 (2020); 2020.","VH: Chain J, heavy chain of 4A8 / VL: Chain N, light chain of 4A8",2022-03-01
695,CV30,SARS-CoV-2,Homo sapiens (human),xvqlvesgggliqpggslrlscaasgvivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldvsggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,xivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Hurlburt,N.K. et al.; Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation; bioRxiv (2020); 2020.","VH: Chain H, CV30 Fab Heavy chain / VL: Chain L, CV30 Fab Kappa chain",2022-03-01
696,C105,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargegwelpydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssxlyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqppsasgspgqsvtisctgtssdvggykyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyegsnnfvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies; Cell 182 (4), 828-842 (2020); 2020.","VH: Chain H, C105 Fab Heavy Chain / VL: Chain L, C105 Fab Light Chain",2022-03-01
701,C105,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargegwelpydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthhhhhh,qsaltqppsgsgspgqsvtisctgtssdvggykyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyegsnnfvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Barnes,C.O. et al.; Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies; Cell 182 (4), 828-842 (2020); 2020.","VH: Chain H, C105 Heavy Chain / VL: Chain L, C105 Light Chain",2022-03-01
702,REGN10987,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Hansen,J. et al.; Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail; Science 369 (6506), 1010-1014 (2020); 2020.","VH: Chain C, REGN10987 antibody Fab fragment heavy chain / VL: Chain A, REGN10987 antibody Fab fragment light chain",2022-03-01
703,REGN10933,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Hansen,J. et al.; Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail; Science 369 (6506), 1010-1014 (2020); 2020.","VH: Chain B, REGN10933 antibody Fab fragment heavy chain / VL: Chain D, REGN10933 antibody Fab fragment light chain",2022-03-01
704,AB23-FAB-HEAVY,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarpqggsswyrdyyygmdvwgqgttvtvss,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,"Cao,Y. et al.; Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells; Cell 182 (1), 73-84 (2020); 2020.","VH: Chain H, Ab23-Fab-Heavy Chain / VL: Chain L, Ab23-Fab-Light Chain",2022-03-01
705,not found,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslktrvtisvdtsknqfslklssvtaadtavyycaravvgivvvpaagrrafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepks,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Ju,B. et al.; Human neutralizing antibodies elicited by SARS-CoV-2 infection; Nature 584 (7819), 115-119 (2020); 2020.","VH: Chain H, antibody heavy chain / VL: Chain L, antibody light chain",2022-03-01
706,CB6,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsmntlflqmnslraedtavyycarvlpmygdyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkththhhhhh,divmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2; Nature 584 (7819), 120-124 (2020); 2020.","VH: Chain C, CB6 heavy chain / VL: Chain D, CB6 light chain",2022-03-01
708,S309,not determined,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvss,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveik,"Pinto,D. et al.; Structural and functional analysis of a potent sarbecovirus neutralizing antibody; bioRxiv (2020); 2020.","VH: Chain D, S309 neutralizing antibody heavy chain / VL: Chain E, S309 neutralizing antibody light chain",2022-03-01
713,S309,not determined,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgypftsygiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtstttgymelrrlrsddtavyycardytrgawfgesliggfdnwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,eivltqspgtlslspgeratlscrasqtvsstslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqhdtsltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Pinto,D. et al.; Structural and functional analysis of a potent sarbecovirus neutralizing antibody; bioRxiv (2020); 2020.","VH: Chain E, S309 antigen-binding (Fab) fragment, heavy chain / VL: Chain F, S309 antigen-binding (Fab) fragment, light chain",2022-03-01
716,B38,SARS-CoV-2,Homo sapiens (human),gdevqlvesggglvqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycareaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,gddivmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Wu,Y. et al.; A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2; Science 368 (6496), 1274-1278 (2020); 2020.","VH: Chain H, Heavy chain of B38 / VL: Chain L, Light chain of B38",2022-03-01
717,CR3022,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Yuan,M. et al.; A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV; Science 368 (6491), 630-633 (2020); 2020.","VH: Chain H, CR3022 Fab heavy chain / VL: Chain L, CR3022 Fab light chain",2022-03-01
718,7D10,MERS-CoV,Mus musculus (house mouse),gggsgggsgggsevqlvesgaevvkpgasvkmsckasgypftsynihwikqtpgqglewigaiypgngdtsytqkfkvkatltsdkssstaymqlssltsedsavyfcarygnypsyamdywgqgtsvtvss,divmtqspasltvslgqratiscrasksvsasgynylhwyqqrpgqppklliylafnlesgvparfngsgsgtdftlnihpveeedaatyycqhsrdlpftfgsgtkleik,"Zhou,H. et al.; Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein; Nat Commun 10 (1), 3068 (2019); 2019.","VH: Chain F, VH of 7D10 / VL: Chain G, VL of 7D10",2022-03-01
721,LCA60,SARS-CoV,Homo sapiens (human),evqllesggglvkpggslrlsceasgltfsnvwmswvrqapgkglewvgrikrksegattdygapvkgrftlsrddskntvylqmnslkiddtavyycstltrggdvwsssyyfdywgqgalvtvss,qsaltqpasvsgspgqsitisctgtssdvgtydlvswyqqhpgkspklmiyadikrpsgvshrfsgsksgntasltisglqsadeadyycclyagsstsvifgggtkvt,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.","VH: Chain H, LCA60 heavy chain / VL: Chain L, LCA60 light chain",2022-03-01
724,S230,SARS-CoV,Homo sapiens (human),qaqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgttvavss,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.","VH: Chain H, S230 heavy chain / VL: Chain L, S230 light chain",2022-03-01
729,S230,SARS-CoV,Homo sapiens (human),qaqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgttvavssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.","VH: Chain H, S230 antigen-binding (Fab) fragment, heavy chain / VL: Chain L, S230 antigen-binding (Fab) fragment, light chain",2022-03-01
730,LCA60,SARS-CoV,Homo sapiens (human),evqllesggglvkpggslrlsceasgltfsnvwmswvrqapgkglewvgrikrksegattdygapvkgrftlsrddskntvylqmnslkiddtavyycstltrggdvwsssyyfdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,qsaltqpasvsgspgqsitisctgtssdvgtydlvswyqqhpgkspklmiyadikrpsgvshrfsgsksgntasltisglqsadeadyycclyagsstsvifgggtkvtgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Walls,A.C. et al.; Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion; Cell 176 (5), 1026-1039 (2019); 2019.","VH: Chain I, LCA60 antigen-binding (Fab) fragment, heavy chain / VL: Chain M, LCA60 antigen-binding (Fab) fragment, light chain",2022-03-01
732,CDC2-C2,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsiyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycaregghqgycsggscydfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkglevlfq,dvvmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpafgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J. Virol. 92 (10), e02002-17 (2018); 2018.","VH: Chain H, Antibody CDC2-C2 heavy chain / VL: Chain L, Antibody CDC2-C2 light chain",2022-03-01
734,JC57-14,SARS-CoV,Macaca mulatta (Rhesus monkey),qvqlqesgpglvkpsetlsltcavsgdsissnywswirqppgkglewigrfsgsggstdfnpslksrvtistdtsknqfslnlrsvtaadtavyycaktysgtfdywgqgvlvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveia,diqmtqspsslsasvgdrvtitcrasqdinnylswyqqkpgkapkpliyyassletgvpsrfsgsrsgtdytltisslqledfatyycqqynnspysfgqgtkveikrtvaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlssteyqshkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J Virol 92 (10), e02002-17 (2018); 2018.","VH: Chain H, JC57-14 Heavy chain / VL: Chain L, JC57-14 Light chain",2022-03-01
736,JC57-14,SARS-CoV,Macaca mulatta (Rhesus monkey),qvqlqesgpglvkpsetlsltcavsgdsissnywswirqppgkglewigrfsgsggstdfnpslksrvtistdtsknqfslnlrsvtaadtavyycaktysgtfdywgqgvlvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggsk,diqmtqspsslsasvgdrvtitcrasqdinnylswyqqkpgkapkpliyyassletgvpsrfsgsrsgtdytltisslqledfatyycqqynnspysfgqgtkveikrtvaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlssteyqshkvyacevthqglsspvtksfnrgec,"Wang,L. et al.; Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape; J Virol 92 (10), e02002-17 (2018); 2018.","VH: Chain H, JC57-14 Heavy chain / VL: Chain L, JC57-14 Light chain",2022-03-01
740,MCA1,SARS-CoV,Homo sapiens (human),atrleesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaskqgdyydrtsyafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkts,dveltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Chen,Z. et al.; Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset; J. Infect. Dis. 215 (12), 1807-1815 (2017); 2017.","VH: Chain B, MCA1 heavy chain / VL: Chain C, MCA1 light chain",2022-03-01
741,4C2,MERS-CoV,Mus musculus (house mouse),dvklvesggglvkpggslklscaasgftfssytmswvrqtpekrlewvatissggsytyypdsvkgrftisrdnakntlylqmsslksedtamyyctrdgndydywgqgttltvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcg,diqmtqttsslsaslgdrvtiscrasqdisnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcqqgntlprtfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Li,Y. et al.; A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein; Cell Res. 25 (11), 1237-1249 (2015); 2015.","VH: Chain C, 4C2 heavy chain / VL: Chain D, 4C2 light chain",2022-03-01
743,H11B11-FAB,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfidyymnwvrqapgkglewvgfirnkandytteystsvkgrftisrdnskntlylqmnslraedtavyycarhmyddgfdfwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveshhhhhhhh,diqmtqspsslsasvgdrvtitcrasssvrymhwyqqkpgkapklliydtsklasgvpsrfsgsgsgtdytltisslqpedfatyycqqwsynpltfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Du,Y. et al.; A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants; Nat Commun 12 (1), 5000 (2021); 2021.","VH: Chain C, h11B11-Fab / VL: Chain D, h11B11-Fab",2022-03-01
745,8D3,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgkslewigginpnigdtsynqnfkgkatltvdrssstaymelrsltsedsavyycardgypyyyaldhwgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgckpcictvpevssvfifppkpkdvltitltpkvtcvvvdiskddpevqfswfvddvevhtaqtqpreeqfnstfrsvselpimhqdwlngkefkcrvnsaafpapiektisktkgrpkapqvytipppkeqmakdkvsltcmitdffpeditvewqwngqpaenykntqpimdtdgsyfvysklnvqksnweagntftcsvlheglhnhhtekslshspgk,divmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkaliystsyrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynsypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Cong,Y. et al.; Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies; Nat Commun (2022); 2022.","VH: Chain A, The heavy chain of 8D3 / VL: Chain B, The light chain of 8D3",2022-03-01
746,ANTI-H5N1,SARS-CoV-2,Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgkslewigginpnigdtsynqnfkgkatltvdrssstaymelrsltsedsavyycardgypyyyaldhwgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkgyfpepvtvtwnsgslssgvhtfpavlqsdlytlsssvtvpsstwpsetvtcnvahpasstkvdkkivprdcgckpcictvpevssvfifppkpkdvltitltpkvtcvvvdiskddpevqfswfvddvevhtaqtqpreeqfnstfrsvselpimhqdwlngkefkcrvnsaafpapiektisktkgrpkapqvytipppkeqmakdkvsltcmitdffpeditvewqwngqpaenykntqpimdtdgsyfvysklnvqksnweagntftcsvlheglhnhhtekslshspgk,divmtqsqkfmstsvgdrvsvtckasqnvgtnvawyqqkpgqspkaliystsyrysgvpdrftgsgsgtdftltisnvqsedlaeyfcqqynsypytfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Cong,Y. et al.; Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies; Nat Commun (2022); 2022.","VH: Chain D, Anti-H5N1 hemagglutinin monoclonal anitbody H5M9 heavy chain / VL: Chain E, The light chain of 8D3 fab",2022-03-01
747,CC40.8,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyvmtwarqapgkglewvsaisgtgytyyadsvkgrftvsrdnskntlflqmsslraedtavyycaitmapvvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepksc,syeltqppsvsvspgqtaritcsgdalpkryaywyqqksgqapilviyedkkrpsgiperlsgsksgtvatltisgaqvedeadyycystdssgnhavfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshksyscqvthegstvektvaptecs,"Zhou,P. et al.; A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection; Sci Transl Med, eabi9215 (2022) In press; 2022.","VH: Chain H, CC40.8 Fab heavy chain / VL: Chain L, CC40.8 Fab light chain",2022-03-01
748,S-E6,SARS-CoV-2,Homo sapiens (human),qvtlresgpglvkpsetlsltcavsggslssvnyywswirqhpgkglewigyiyysgstnynpslksrvtmsldtsknqfslklssvtaadtavyycatpgaimgalhiwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,qavltqpssasstpgqrviiscsgsssnigsntvswyqqvpgaapklliyfdyrrpsgvpdrfsgtrsgtsaslgisglqsedeadyycaawddslsawvfgrgtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Qiang,M. et al.; Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago; Adv Sci (Weinh) 9 (1), e2102181 (2022); 2021.","VH: Chain M, S-E6 Fab heavy chain / VL: Chain N, S-E6 Fab light chain",2022-03-01
750,S-B8,SARS-CoV-2,Homo sapiens (human),qvqlvqsgggliqpggslrlscaasgftvslshmnwvrqapgkglewvsitygdgnsdyadsvkgrftisrdnskntlylqmnslraedtavyycareyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyslpltfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Qiang,M. et al.; Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago; Adv Sci (Weinh) 9 (1), e2102181 (2022); 2021.","VH: Chain M, S-B8 Fab heavy chain / VL: Chain N, S-B8 Fab light chain",2022-03-01
752,RBD-CHAB15,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqleesgpglvqpsqslsitctvsdfslttygvhwvrqspgkglewlgviwsggstdynaafisrlsiskdnsksqvffkmnslqtndtaiyycarmgdgyyvgamdywgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,diqltqspailsvspgervsfscrasqsigtsihwyqqrtngsprhlikyasesisgipsrfsgsgsgtdftltingvesediadyycqqghnwpltfgagtklelkratvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yang,T.J. et al.; Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function; Nat Struct Mol Biol 28 (9), 731-739 (2021); 2021.","VH: Chain E, RBD-chAb15, heavy chain / VL: Chain Q, RBD-chAb15, light chain",2022-03-01
754,RBD-CHAB15,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqleesgpglvqpsqslsitctvsdfslttygvhwvrqspgkglewlgviwsggstdynaafisrlsiskdnsksqvffkmnslqtndtaiyycarmgdgyyvgamdywgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,divmtqsqkfmstsvgdrvsvtckssqnvgtnvawyqqkpgqspkaliysasyrysgvpdhftgsgsgtdftltisnvqsadlaeyfcqqynnypwtfgggtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yang,T.J. et al.; Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function; Nat Struct Mol Biol 28 (9), 731-739 (2021); 2021.","VH: Chain F, RBD-chAb15, heavy chain / VL: Chain N, RBD-chAb45, light chain",2022-03-01
757,RBD-CHAB45,"SARS-CoV-2, Spike protein RBD",Homo sapiens (human),evqlqqsgpelvkpgasvkiscktsgytfteytiywvkqslgkslewiggnnpnnddttykqffkgkatltvdkssstaymelrsltsedsavyycardgypyyyaldfwgqgtsvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspg,diqltqspailsvspgervsfscrasqsigtsihwyqqrtngsprhlikyasesisgipsrfsgsgsgtdftltingvesediadyycqqghnwpltfgagtklelkratvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Yang,T.J. et al.; Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function; Nat Struct Mol Biol 28 (9), 731-739 (2021); 2021.","VH: Chain H, RBD-chAb45, heavy chain / VL: Chain O, RBD-chAb15, light chain",2022-03-01
758,F26G19,SARS-CoV,Mus musculus (house mouse),evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiep,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleikradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Pak,J.E. et al.; Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain; J. Mol. Biol. 388 (4), 815-823 (2009); 2008.","VH: Chain B, F26G19 Fab / VL: Chain C, F26G19 Fab",2022-03-01
760,DH851.3,not determined,Macaca mulatta (Rhesus monkey),qvtlmesgpalvkvtqtlavtctfsgfsirdsgkgvawirqppggalewltsiywddtkyhdtslkprltifrdtsqtqvililtnmapldtatyycgrinngggwkdhidfwgpgllvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgg,altqppsvsksleqsvtisctgtttgnsvswyqchsgtaprlliydvnkrpsgvsdrfsgskshntasltifglqaedeadyycgsygsggsllfgggtrltvlgqpxkasptvtlfppsseelqankatlvclisdfypgvvkvawkadgsavnagvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvapaec,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.","VH: Chain q, DH851.3 heavy chain / VL: Chain r, DH851.3 light chain",2022-03-01
761,DH851.3,not determined,Macaca mulatta (Rhesus monkey),qvtlmesgpalvkvtqtlavtctfsgfsirdsgkgvawirqppggalewltsiywddtkyhdtslkprltifrdtsqtqvililtnmapldtatyycgrinngggwkdhidfwgpgllvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrve,altqppsvsksleqsvtisctgtttgnsvswyqchsgtaprlliydvnkrpsgvsdrfsgskshntasltifglqaedeadyycgsygsggsllfgggtrltvlgqpxkasptvtlfppsseelqankatlvclisdfypgvvkvawkadgsavnagvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvap,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.","VH: Chain p, DH851.3 heavy chain / VL: Chain o, DH851.3 light chain",2022-03-01
766,DH898.1,not determined,Homo sapiens (human),qdlllqsgaevrepgasvtvscqasnytfpdyyihwvrlvpgqglewlgemkpkvgvtnvskkirdrlfmtadtstdtaymvlsaltpgdtaiyyctrlepdflsgwahwgkgvlvtvspastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrve,eivmtqtplslsvtpgepaslscrssasllhgngntylhwylrkagqspqllifggskrvpgisdrfigsgagtnftlkissveaddvgfyycaqgvafpwtfgqgtkveikravaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgvlktgnsqesvteqdskdntyslsstltlsntdyqshnvyacevthqglsspvtksfnrge,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2021.","VH: Chain i, DH898.1 heavy chain / VL: Chain j, DH898.1 light chain",2022-03-01
770,DH717.1,not determined,Homo sapiens (human),qvqlqesgpglvkpsetlsltcavsgvsindgydwtwirqtpgkglewigyvfgrsgnfnlnpslrnrgiiskdtcknqfslnlnsataadtavyfcargmeglfaaynsldvwgrgllvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveikt,altqppsvsgspgqsviisctgtssdigqynsvswyqqhpdkapklviygvtsrpsgvsdrfsgskygdtasltisglqaedeadyycsshadenmalfgggtrltvlgqpkasptvtlfppsseelqankatlvclisdfypgvvkvawkadgsavnagvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvapa,"Acharya,P. et al.; Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques; bioRxiv (2020); 2020.","VH: Chain H, DH717.1 heavy chain Fab fragment / VL: Chain L, DH717.1 light chain Fab fragment",2022-03-01
774,CR3022,SARS-CoV-2,Homo sapiens (human),qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvvsrrlppsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Wu,N.C. et al.; A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody; PLoS Pathog 16 (12), e1009089 (2020); 2020.","VH: Chain H, CR3022 heavy chain / VL: Chain L, CR3022 light chain",2022-03-01
775,ACE2-TARGETING,SARS-CoV-2,synthetic construct,evqlvesggglvqpggslrlscaasgftfidyymnwvrqapgkglewvgfirnkandytteystsvkgrftisrdnskntlylqmnslraedtavyycarhmyddgfdfwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapefeggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslspgk,diqmtqspsslsasvgdrvtitcrasssvrymhwyqqkpgkapklliydtsklasgvpsrfsgsgsgtdytltisslqpedfatyycqqwsynpltfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants; Unpublished; 2021.","VH: humanized ACE2-targeting immunoglobulin heavy chain, partial [synthetic construct] / VL: humanized ACE2-targeting immunoglobulin light chain, partial [synthetic construct]",2022-03-01
776,not found,not determined,Mus musculus (house mouse),dvqlvesggglvqpggsrklscsasgfafssfgmhwvrqapekglewvayissgsgtiyyadtvkgrftisrddpkntlflqmtslrsedtamyycvrsiyyygsspfdfwgqgttltvssakttppsvyplapgcgdttgssvtlgclvkgyfpesvtvtwnsgslsssvhtfpallqsglytmsssvtvpsstwpsqtvtcsvahpassttvdkkleps,divmtqatssvpvtpgesvsiscrssksllhsngntylywflqrpgqspqlliyrmsnlasgvpdrfsgsgsgtaftltisrleaedvgvyycmqhleypltfgagtklelkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrn,"Isaikina,P. et al.; Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist; Sci Adv 7 (25) (2021); 2021.","VH: Chain H, Fab antibody fragment heavy chain / VL: Chain F, Fab antibody fragment light chain",2022-03-01
777,not found,SARS-CoV-2,Homo sapiens (human),evqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigevnhsgstnynpslksrvtisvdtsknqlslklnsvtaadtavyycargntmvrgviipfeywdkgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapeaaggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslg,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Song,D. et al.; Structure and function analysis of a potent human neutralizing antibody CA521LALA against SARS-CoV-2; Unpublished; 2021.","VH: anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens] / VL: anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-01
778,1C4,not determined,Macaca fascicularis (crab-eating macaque),evqlvesggglakpggslrlscaasgftfstyamhwvrqapgkglewisginsgggstwytasvkgrftisrdnskstlslqmnslrtedtavyycakdggnaifglvitnygldswgqgavvtvssastkgpsvfplapssrstsestaalgclvkdyfpepvtvswnsgsltsgvhtfpavlqssglyslssvvtvpssslgtqtyvcnvnhkpsntkvdkrveiktcgggskppthhhhhh,qsvltqppsasgapgqsvtiscsgsssnfgsnhvywyqqlsgkapklliynnnrrpsgvpdrfsgsksgtsaslaisglqsedeadyycsvwdsslnnvlfgggtrltvlgqpkaapsvtlfppsseelqankatlvclisdfypgvvkvawkadgnsvntgvetttpskqsnnkyaassylsltsdqwkshksyscqvthegstvektvapaecs,"Darricarrere,N. et al.; Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates; Sci Transl Med 13 (583) (2021); 2021.","VH: Chain I, 1C4 Fab heavy chain / VL: Chain J, 1C4 Fab light chain",2022-03-01
781,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgnnkyyadsvkgrftissdnskntlylqmnslraedtavyycakdlaawgpycsstncytggmdvwgqgttvtvss,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddgdrpsgiperfsgsnsgntatlaisrveagdeadyycqvwdssshwvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
782,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyyctteepgagslyyyyymdvwgkgttvtvss,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwprtfgqgtkvdik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
783,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedggtiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatglqaarrdyyyygmdvwgqgttvtvss,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprllifdasiratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgqgtkleik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
784,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdpyypgsvkgrftisrenaknslylqmnslragdtavyycargggryydfwsgyygdyyhyymdvwgkgttvtvss,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqspqlliyevssrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgihlqvgitfgpgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
785,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifdttnyaqkfqgrvtitadeststaymelsslrsedtavyycarvgdydssgyysdywgqgtlvtvss,eivmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppavtfgpgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
786,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitsssgyrnyadsvkgrftisrdnaknslylqmsslraedtavyycardsaldergyssgwhpphwgqgtlvtvss,eivltqspstlsasvgdrvtiscrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsrsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
787,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskttlylqmnslktedtavyycsrsillyyyastgyhheldywgqgtlvtvss,qpvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytiistlgvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
788,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftlssyamywvrqapgkglewvavisydgtnkyyadsvkgrftisrdnskntlflqmnslraedtavyycarpysgsyreyfqhwgqgtlvtvss,dvvmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpitfgqgtrleik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
789,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyaihwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarglggnyyavdywgqgtlvtvss,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqqgtfgqgtkleik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
790,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmntlraedtavyycarsstyytgfdywgqgtlvtvss,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydgsnhqvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
791,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvsaissnggstyyadsvkgrftisrdnskntlylqmsslraedtavyycvkdwavliqmpfdywgqgtlvtvss,qavvtpepsltvspggtvtltcgssigavtgghfpywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgaqpededeyycllsnsgarpvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
792,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlsctasgftlraydmiwvrqapgkglewvsysgrshsayyadsvkgrftisrddaenslylhmntlragdtalyycardrtycssgscyaydffygmdvwgqgttvtiss,qsvltqppsvsaapgqkvtiscsgrssnigdnyvswyqhlpgaapklliyennkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtsdsslsaggvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
793,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregivgattgfdywgqgtlvtvss,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnpsfgtgtkvtvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
794,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdqsegygenymdvwgkgttvtvss,syeltqppsvsvspgqaaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttatltisgvqaedeadyycqsadssdtwvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
795,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargksptvvtpwfdywgqgtlvtvss,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalwvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
796,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsirsdfwswirqfpgkglewigyiyysgstnynpslesrvtisvdtsknefslklnyvtaadtaiyycaretrwnwldswgqgtlvtvss,divmtqspdslavslgerasinckssqtisyisnnknylawyqqkpgqpprlliywastresgvpdrfsgggfgtdftltisslqaedvavyycqqyfntpwtfgqgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
797,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscvapgftlggygmhwvrqapgkglewvglisydgsvqkygssvkgrftiskdnskntlylemnslraddtavyfcvkgaslgdnwgqgtlvtvss,eivmtqsplslpvtlgqpasiscrssqslvysdgdtymswfhqrpgqsprrliykvsnrdfgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpytfgpgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
798,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyvmtwarqapgkglewvsaisgtgytyyadsvkgrftvsrdnskntlflqmsslraedtavyycaitmapvvwgqgttvtvss,eivmtqsplslpvtlgqpasiscrssqslvysdgdtymswfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpytfgpgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
799,CROSS-REACTIVE,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscvasgftfsnygmhwvrqapgkglewvavmsydgsvtyygdsvrgrftisrdnskntlylqmsslrtddtgvyycakgqplddiwglgtlvtvss,syeltqppsvsvspgqtaritcsgdalpkryaywyqqksgqapilviyedkkrpsgiperlsgsksgtvatltisgaqvedeadyycystdssgnhavfgggtqltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.","VH: cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens] / VL: cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-01
800,D12,MERS-CoV,Mus musculus (house mouse),evklvesggglvkpggslklscaasgftfssyamswvrqtpekrlewvatissggtytyypdsvkgrftisrdnaentlylqmsslrsedtamyycvrdgnsmdywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiepr,diqmtqttsslsaslgdrvtiicrasqdinnylnwyqqkpdgtvklliyytsrlhsgvpsrfsgsgsgsdysltisnleqediatyfcqqantlpptfgagtklelrradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Wang,L. et al.; Evaluation of candidate vaccine approaches for MERS-CoV; Nat Commun 6, 7712 (2015); 2015.","VH: Chain A, D12 Fab Heavy chain / VL: Chain B, D12 Fab light chain",2022-03-01
804,M336,MERS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtasyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstscnrgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsgqaghhhhhhgdykddddkg,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Ying,T. et al.; Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody; Nat Commun 6, 8223 (2015); 2015.","VH: Chain D, Heavy chain of neutralizing antibody m336 / VL: Chain E, Light chain of neutralizing antibody m336",2022-03-01
806,1AF10,SARS-CoV,Mus musculus (house mouse),qvqlqqsgpelvkpgasvkisckasgyafssswmnwvkqrpgqglewigriypgdgetnysekfkgkatltadkssstaymhlssltsvdsavyfcarggyrydpyyamdywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiep,dilltqspailsvspgervslscrasqsigtsihwyqqrtngsprplikyasesisgipsrfsgsgsgtdftlninsvesediadyfcqqtdswpttfgagtklelkradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Reguera,J. et al.; Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies; PLoS Pathog. 8 (8), E1002859 (2012); 2012.","VH: Chain C, monoclonal antibody 1AF10, heavy chain / VL: Chain D, monoclonal antibody 1AF10, light chain",2022-03-01
808,S/RBD,"SARS-CoV-2, Spike protein RBD",synthetic construct,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,W. et al.; Phage display library derived human Fab against SARS-CoV-2 spike protein receptor binding domain; Unpublished; 2020.","VH: anti-SARS-CoV-2 S/RBD immunoglobulin heavy chain, partial [synthetic construct] / VL: anti-SARS-CoV-2 S/RBD immunoglobulin light chain, partial [synthetic construct]",2022-03-01
809,not found,SARS-CoV,Mus musculus (house mouse),mkcswvifflmavviginsevqlqqsgaelvrsgasvklsctasgfnikdyymhwvkqrpeqglewigwidpengyteyapkfqgkatvtadtssntaylqlssltsedtavyycnafyyrydafdywgqgttltvss,mesqiqvfvfvflwlsgvdgdivmtqshkfmstsvgdrvsitckasqdvstavawyqqkpgqspklliysasyrytgvpvrftgsgsgtdftftissvqaedlavyycqqhystpytfgggtkleik,"Castilla,J. et al.; Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus-neutralizing antibodies; J. Virol. 71 (7), 5251-5258 (1997); 1997.","VH: monoclonal antibody gamma one chain variable region, partial [Mus musculus] / VL: monoclonal antibody kappa chain variable region, partial [Mus musculus]",2022-03-01
